[No authors listed]. Vinpocetine Monograph. Altern Med Rev. 2002;7(3): 240-3. Available at: http://www.altmedrev.com/publications/7/3/240.pdf Accessed 7/25/2012.
AAN. American Academy of Neurology. Monoclonal Antibodies for Alzheimer's Resources. Accessed 9/5/2024, https://www.aan.com/tools-resources/monoclonal-antibodies-alzheimers
Abraham CR, Li A. Aging-suppressor Klotho: Prospects in diagnostics and therapeutics. Ageing Res Rev. Dec 2022;82:101766. doi:10.1016/j.arr.2022.101766. https://pubmed.ncbi.nlm.nih.gov/36283617/
Abris GP, Shavlik DJ, Mathew RO, et al. Cause-specific and all-cause mortalities in vegetarian compared with those in nonvegetarian participants from the Adventist Health Study-2 cohort. Am J Clin Nutr. Oct 2024;120(4):907-917. doi:10.1016/j.ajcnut.2024.07.028. https://pubmed.ncbi.nlm.nih.gov/39098708/
Adám-Vizi V. “Neuroprotective Effect of Sodium Channel Blockers in Ischemia: The Pathomechanism of Early Ischemic Dysfunction” [in Hungarian]. Orv Hetil. 141.23 (2000): 1279-86.
Agarwal P, Leurgans SE, Agrawal S, et al. Association of Mediterranean-DASH Intervention for Neurodegenerative Delay and Mediterranean Diets With Alzheimer Disease Pathology. Neurology. May 30 2023;100(22):e2259-e2268. doi:10.1212/WNL.0000000000207176. https://pubmed.ncbi.nlm.nih.gov/36889921/
Aggarwal BB, et al. “Suppression of the Nuclear Factor-KappaB Activation Pathway by Spice-Derived Phytochemicals: Reasoning for Seasoning.” Ann N Y Acad Sci. 1030 (2004): 434-41.
Akbar M, et al. “Docosahexaenoic Acid: A Positive Modulator of Akt Signaling in Neuronal Survival.” Proc Natl Acad Sci USA. 102.31 (2005): 10858-63.
Al-Amin MM, Mahmud W, Pervin MS, Ridwanul Islam SM, Ashikur Rahman M, Zinchenko A. Astaxanthin ameliorates scopolamine-induced spatial memory deficit via reduced cortical-striato-hippocampal oxidative stress. Brain research. 2019;1710:74-81.
Alghazwi M, Smid S, Musgrave I, Zhang W. In vitro studies of the neuroprotective activities of astaxanthin and fucoxanthin against amyloid beta (Abeta1-42) toxicity and aggregation. Neurochemistry international. 2019;124:215-224.
Alkadhi K and Eriksen J. The complex and multifactorial nature of Alzheimer's disease. Curr Neuropharmacol. 2011 Dec;9(4):586.
Alzheimer’s Association. Criteria for Diagnosis and Staging of Alzheimer's Disease. 2025b. Accessed 7/23/2025. https://www.alz.org/research/for_researchers/diagnostic-criteria-guidelines
Alzheimer’s Association. Risk Factors. 2012. Available at: http://www.alz.org/alzheimers_disease_causes_risk_factors.asp?gclid=CLyKuavN8bACFQeCnQoduQNh-Q. Accessed June 28, 2012b.
Alzheimer’s Association. Stages of Alzheiemer’s. 2025a. Accessed 08/28/2025. https://www.alz.org/alzheimers-dementia/stages
Ames BN, et al. “Delaying the Mitochondrial Decay of Aging with Acetylcarnitine.” Ann N Y Acad Sci. 1033 (2004): 108-16.
Amtul Z, et al. “Structural Insight Into the Differential Effects of Omega-3 and Omega-6 Fatty Acids on the Production of Abeta Peptides and Amyloid Plaques.” J Biol Chem. 2011 Feb;286(8):6100-6107 .
Angelucci F, Cechova K, Amlerova J, Hort J. Antibiotics, gut microbiota, and Alzheimer's disease. J Neuroinflammation. 2019;16(1):108.
Annweiler C, Rolland Y, Schott AM, et al. Higher Vitamin D Dietary Intake Is Associated with Lower Risk of Alzheimer's Disease: A 7-Year Follow-Up. [In Eng] J Gerontol A Biol Sci Med Sci. 2012 Apr 13;
Antonioni A, Raho EM, Di Lorenzo F, Manzoli L, Flacco ME, Koch G. Blood phosphorylated Tau217 distinguishes amyloid-positive from amyloid-negative subjects in the Alzheimer's disease continuum. A systematic review and meta-analysis. J Neurol. 2025;272(3):252. doi:10.1007/s00415-025-12996-3. https://pubmed.ncbi.nlm.nih.gov/40047958/
Aprahamian I, Santos FS, dos Santos B, et al. Long-term, low-dose lithium treatment does not impair renal function in the elderly: a 2-year randomized, placebo-controlled trial followed by single-blind extension. The Journal of clinical psychiatry. Jul 2014;75(7):e672-8. doi:10.4088/JCP.13m08741. http://www.psychiatrist.com/jcp/article/pages/2014/v75n07/v75n0702.aspx
Arakawa M and Ito Y. “N-acetylcysteine and Neurodegenerative Diseases: Basic and Clinical Pharmacology.” Cerebellum. (2007):1-7. Epub ahead of print.
Aranda-Abreu GE, et al. “Rehabilitating a Brain with Alzheimer’s: A Proposal.” Clin Interv Aging. 6 (2011): 53-9.
Araujo JA, et al. “Improvement of Short-Term Memory Performance in Aged Beagles by a Nutraceutical Supplement Containing Phosphatidylserine, Ginkgo biloba, Vitamin E, and Pyridoxine.” Can Vet J. 49.4 (2008): 379-85.
Ardebili SM, Yeghaneh T, Gharesouran J, et al. Genetic association of TNF-α-308 G/A and -863 C/A polymorphisms with late onset Alzheimer’s disease in Azeri Turk population of Iran.” J Res Med Sci. 16.8 (2011): 1006-1013.
Aron L, Ngian ZK, Qiu C, et al. Lithium deficiency and the onset of Alzheimer's disease. Nature. Aug 6 2025;doi:10.1038/s41586-025-09335-x. https://www.ncbi.nlm.nih.gov/pubmed/40770094
Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurology. 2024;81(3):255-263. doi:10.1001/jamaneurol.2023.5319. https://pubmed.ncbi.nlm.nih.gov/38252443/
Bacsi A, Aguilera-Aguirre L, German P, Kruzel ML, Boldogh I. Colostrinin decreases spontaneous and induced mutation frequencies at the hprt locus in Chinese hamster V79 cells. Journal of experimental therapeutics & oncology.2006;5(4):249-259.
Bacsi A, Woodberry M, Kruzel ML, Boldogh I. Colostrinin delays the onset of proliferative senescence of diploid murine fibroblast cells. Neuropeptides.Apr 2007;41(2):93-101.
Bai DL, et al. “Huperzine A: A Potential Therapeutic Agent for Treatment of Alzheimer’s Disease.” Curr Med Chem. 7.3 (2000): 355-74.
Bailey ME, Wang AC, Hao J, et al. teractive effects of age and estrogen on cortical neurons: implications for cognitive aging. Neuroscience. 2011 Sep 15;191:148-58.
Balestreri R, Fontana L, Astengo F. A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J Am Geriatr Soc. 1987 May;35(5):425-30.
Baloyannis SJ, and Baloyannis IS. The vascular factor in Alzheimer's disease: A study in Golgi technique and electron microscopy. J Neurol Sci. 2012 Aug 2. [Epub ahead of print]
Barbagallo M, et al. “Altered Ionised Magnesium Levels in Mild-to-Moderate Alzheimer’s Disease.” Magnes Res. 24.3 (2011): S115-21.
Barbagallo Sangiorgi G, et al. "Alpha-Glycerophosphocholine in the mental recovery of cerebral ischemic attacks." An Italian multicenter clinical trial. Ann NY Acad Sci 1994; 717:253-69.
Bardgett ME, et al. “Magnesium Deficiency Impairs Fear Conditioning in Mice.” Brain Res. 1038.1 (2005): 100-6.
Barron AM, Pike CJ. “Sex hormones, aging, and Alzheimer’s disease.” Front Biosci (Elite Ed). 2012 Jan 1;4:976-97.
Baum L, et al. “Curcumin Interaction with Copper and Iron Suggests One Possible Mechanism of Action in Alzheimer’s Disease Animal Models.” J Alzheimers Dis. 6.4 (2004): 367-77.
Baum L, Lam CW, Cheung SK, et al. Six-Month Randomized, Placebo-Controlled, Double-Blind, Pilot Clinical Trial of Curcumin in Patients with Alzheimer Disease. [In eng] J Clin Psychopharmacol. 2008 Feb; 28(1): 110-3.
Begum AN, et al. “Curcumin Structure-Function, Bioavailability, and Efficacy in Models of Neuroinflammation and Alzheimer’s Disease.” J Pharmacol Exp Ther. 326.1 (2008): 196-208.
Belluck P, Robbins R. Three F.D.A. Advisers Resign Over Agency's Approval of Alzheimer's Drug. The New York Times [online]. Updated 9/2/2021. Accessed 9/16/2024, https://www.nytimes.com/2021/06/10/health/aduhelm-fda-resign-alzheimers.html?
Bendlin BB. Antidiabetic therapies and Alzheimer disease. Dialogues in clinical neuroscience. 2019;21(1): 83-91.
Berry NM, Robinson MJ, Bryan J, Buckley JD, Murphy KJ, Howe PR. Acute effects of an Avena sativa herb extract on responses to the Stroop Color-Word test. Journal of alternative and complementary medicine.Jul 2011;17(7):635-637.
Beydoun MA, et al. Clinical and Bacterial Markers of Periodontitis and Their Association with Incident All-Cause and Alzheimer's Disease Dementia in a Large National Survey. J Alzheimers Dis. 2020;75(1): 157-172.
Biasutti M, Dufour N, Ferroud C, et al. “Cost-Effectiveness of Magnetic Resonance Imaging with a New Contrast Agent for the Early Diagnosis of Alzheimer’s Disease.” PLoS One. 7.4 (2012): e35559.
Bilikiewicz A, Gaus W. Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease. Journal of Alzheimer's disease: JAD.Feb 2004;6(1):17-26.
Blum S, et al. “Memory after Silent Stroke: Hippocampus and Infarcts Both Matter.” Neurology. 78.1 (2012): 38-46.
Boldogh I, Kruzel ML. Colostrinin: an oxidative stress modulator for prevention and treatment of age-related disorders. Journal of Alzheimer's disease: JAD.Apr 2008;13(3):303-321.
Booth S, Talegawkar S, Fung T, et al. USDA Nutrition Evidence Systematic Review (NESR) Systematic Reviews, Rapid Reviews, and Evidence Scans. Dietary Patterns and Risk of Cognitive Decline, Dementia, Alzheimer's Disease, and Mild Cognitive Impairment: A Systematic Review. USDA Nutrition Evidence Systematic Review; 2024. USDA Nutrition Evidence Systematic Review (NESR) Systematic Reviews, Rapid Reviews, and Evidence Scans. https://pubmed.ncbi.nlm.nih.gov/39908392/
Boothby LA, Doering PL. “Vitamin C and vitamin E for Alzheimer’s disease.” Ann Pharmacother. 39.12 (2005):2073-80.
Bourhim M, Kruzel M, Srikrishnan T, Nicotera T. Linear quantitation of Abeta aggregation using Thioflavin T: reduction in fibril formation by colostrinin. Journal of neuroscience methods.Mar 15 2007;160(2):264-268.
Bouteloup V, Villain N, Vidal JS, et al. Cognitive Phenotyping and Interpretation of Alzheimer Blood Biomarkers. JAMA Neurol. 2025;82(5):506-515. doi:10.1001/jamaneurol.2025.0142. https://pubmed.ncbi.nlm.nih.gov/40181683/
Boza-Serrano A, Vrillon A, Minta K, et al. Galectin-3 is elevated in CSF and is associated with Abeta deposits and tau aggregates in brain tissue in Alzheimer's disease. Acta Neuropathol. Nov 2022;144(5):843-859. doi:10.1007/s00401-022-02469-6. https://pubmed.ncbi.nlm.nih.gov/35895141/
Brandalise F, Cesaroni V, Gregori A, Repetti M, Romano C, Orru G, . . . Rossi P. Dietary Supplementation of Hericium erinaceus Increases Mossy Fiber-CA3 Hippocampal Neurotransmission and Recognition Memory in Wild-Type Mice. Evidence-based complementary and alternative medicine : eCAM. 2017;2017:3864340.
Brinton RD. “Investigative Models for Determining Hormone Therapy-Induced Outcomes in Brain: Evidence in Support of a Healthy Cell Bias of Estrogen Action.” Ann N Y Acad Sci. 2005 Jun;1052:57-74.
Brugulat-Serrat A, Salvado G, Operto G, et al. White matter hyperintensities mediate gray matter volume and processing speed relationship in cognitively unimpaired participants. Hum Brain Mapp. Apr 1 2020;41(5):1309-1322. doi:10.1002/hbm.24877. https://pubmed.ncbi.nlm.nih.gov/31778002/
Bryson S. 3 months of TB006 eased, reversed signs of Alzheimer's disease: Trial. Bionews, Inc. Updated 4/21/2023. Accessed 9/13/2024, https://alzheimersnewstoday.com/news/signs-alzheimers-reversed-eased-after-3-months-tb006/
Bubenik GA and Konturek SJ. “Melatonin and aging: prospects for human treatment.” J Physiol Pharmacol. 62.1 (2011): 13-9.
Bukhbinder AS, Ling Y, Hasan O, et al. Risk of Alzheimer's Disease Following Influenza Vaccination: A Claims-Based Cohort Study Using Propensity Score Matching. J Alzheimers Dis. 2022;88(3):1061-1074. doi:10.3233/jad-220361. https://content.iospress.com:443/download/journal-of-alzheimers-disease/jad220361?id=journal-of-alzheimers-disease%2Fjad220361
Burns JM, et al. “Cardiorespiratory Fitness and Brain Atrophy in Early Alzheimer Disease.” Neurology. 71.3 (2008): 210-6.
Butt MS, et al. “Coffee and Its Consumption: Benefits and Risks.” Crit Rev Food Sci Nutr. 51.4 (2011): 363-73.
Butterworth RF. “Evidence for Forebrain Cholinergic Neuronal Loss in Congenital Ornithine Transcarbamylase Deficiency.” Metab Brain Dis. 15.1 (2000): 83-91.
Cai Z. Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease (Review). Molecular medicine reports. May 2014;9(5):1533-1541.
Cai Z, et al. “Mammalian Target of Rapamycin: A Valid Therapeutic Target through the Autophagy Pathway for Alzheimer’s disease?” J Neurosci Res. 90.6 (2012): 1105-18.
Cairns DM, Itzhaki RF, Kaplan DL. Potential Involvement of Varicella Zoster Virus in Alzheimer's Disease via Reactivation of Quiescent Herpes Simplex Virus Type 1. J Alzheimers Dis. 2022;88(3):1189-1200. doi:10.3233/jad-220287. https://content.iospress.com/articles/journal-of-alzheimers-disease/jad220287
Canto C, Houtkooper RH, Pirinen E, et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab.Jun 6 2012;15(6):838-847.
Cao C, et al. “Caffeine Synergizes with Another Coffee Component to Increase Plasma GCSF: Linkage to Cognitive Benefits in Alzheimer’s Mice.” J Alzheimers Dis. 25.2 (2011): 323-35.
Cardinali DP, Furio AM, Brusco LI. “The use of chronobiotics in the resynchronization of the sleep/wake cycle. Therapeutical application in the early phases of Alzheimer’s disease.” Recent Pat Endocr Metab Immune Drug Discov. 5.2 (2011): 80-90.
Carroll JC and Rosario ER. “The Potential Use of Hormone-Based Therapeutics for the Treatment of Alzheimer’s Disease.” Curr Alzheimer Res. 2012 Jan;9(1):18-34.
Casadesus G, Shukitt-Hale B, Stellwagen HM, et al. Nutr Neurosci. 7.5-6 (2004): 309-16.
Caselli RJ, Reiman EM. “Characterizing the Preclinical Stages of Alzheimer’s Disease and the Prospect of Presymptomatic Intervention.” J Alzheimers Dis. (2012) [Epub ahead of print]
Castner SA, Gupta S, Wang D, et al. Longevity factor klotho enhances cognition in aged nonhuman primates. Nat Aging. Aug 2023;3(8):931-937. doi:10.1038/s43587-023-00441-x. https://pubmed.ncbi.nlm.nih.gov/37400721/
Chan A, Paskavitz J, Remington R, Rasmussen S, Shea TB. Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer's disease: a 1-year, open-label pilot study with an 16-month caregiver extension. Am J Alzheimers Dis Other Demen. Dec-2009 Jan 2008;23(6):571-85. doi:10.1177/1533317508325093. https://pubmed.ncbi.nlm.nih.gov/19047474/
Chen HK, Ji ZS, Dodson SE, et al. “Apolipoprotein E4 Domain Interaction Mediates Detrimental Effects on Mitochondria and Is a Potential Therapeutic Target for Alzheimer Disease.” J Biol Chem. 2011 Feb 18;286(7):5215-21.
Chen S, Underwood BR, Jones PB, Lewis JR, Cardinal RN. Association between lithium use and the incidence of dementia and its subtypes: A retrospective cohort study. PLoS Med. Mar 2022;19(3):e1003941. doi:10.1371/journal.pmed.1003941. https://www.ncbi.nlm.nih.gov/pubmed/35298477
Chen SD, Lu JY, Li HQ, et al. Staging tau pathology with tau PET in Alzheimer's disease: a longitudinal study. Transl Psychiatry. 2021;11(1):483. doi:10.1038/s41398-021-01602-5. https://pubmed.ncbi.nlm.nih.gov/34537810/
Cheng F, et al. “Suppression of Amyloid β A11 Antibody Immunoreactivity by Vitamin C: Possible Role Of Heparan Sulfate Oligosaccharides Derived From Glypican-1 By Ascorbate-induced, Nitric Oxide (NO)-catalyzed Degradation.” J Biol Chem, 286.31 (2011): 27559-72.
Cheng Y, et al. “Beneficial Effects of Melatonin in Experimental Models of Alzheimer Disease.” Acta Pharmacol Sin. 27.2 (2006): 129-39.
Chinnici CM, Yao Y, Pratico D. The 5-lipoxygenase enzymatic pathway in the mouse brain: young versus old. Neurobiology of aging. Sep 2007;28(9):1457-1462.
Chi S, Yu JT, Tan MS, Tan L. Depression in Alzheimer's disease: epidemiology, mechanisms, and management. Journal of Alzheimer's disease : JAD. 2014;42(3):739-755.
Chi Y, Sauve AA. Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection. Current opinion in clinical nutrition and metabolic care.Nov 2013;16(6):657-661.
Chiu CH, Chyau CC, Chen CC, Lee LY, Chen WP, Liu JL, . . . Mong MC. Erinacine A-Enriched Hericium erinaceus Mycelium Produces Antidepressant-Like Effects through Modulating BDNF/PI3K/Akt/GSK-3beta Signaling in Mice. International journal of molecular sciences. Jan 24 2018;19(2).
Choudhary MI, et al. “Cholinesterase Inhibiting Withanolides from Withania somnifera.” Chem Pharm Bull Tokyo. 52.11 (2004): 1358-61.
Chowanadisai W, et al. “Pyrroloquinoline quinone stimulates mitochondrial biogenesis through cAMP response element-binding protein phosphorylation and increased PGC-1alpha expression.” J Biol Chem. 285.1 (2010): 142-152.
Christensen LP. “Ginsenosides chemistry, biosynthesis, analysis, and potential health effects.” Adv Food Nutr Res. 55 (2009): 1-99.
Christimann G, Rocha G, Sattler JAG. Bioactive compounds and dietary patterns in Alzheimer's disease. J Alzheimers Dis. Apr 2025;104(3):597-610. doi:10.1177/13872877251319048. https://pubmed.ncbi.nlm.nih.gov/40012188/
Chu J, Li JG, Pratico D. Zileuton improves memory deficits, amyloid and tau pathology in a mouse model of Alzheimer's disease with plaques and tangles. PloS one. 2013;8(8):e70991.
Chu J, Pratico D. The 5-Lipoxygenase as modulator of Alzheimer's gamma-secretase and therapeutic target. Brain research bulletin. Sep 2016;126(Pt 2):207-212.
Chu J, Pratico D. Pharmacologic blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer's disease transgenic mouse model involvement of gamma-secretase. The American journal of pathology. Apr 2011;178(4):1762-1769.
Ciabattoni G, et al. “Determinants of Platelet Activation in Alzheimer’s Disease.” Neurobiol Aging. 28.3 (2007): 336-72. Epub ahead of print January 24, 2006.
Clinicaltrials.gov. NCT01617577. Efficacy and Safety of Filgrastim in Alzheimer's Disease (FFAD) Available at: http://clinicaltrial.gov/ct2/show/NCT01617577?term=Granulocyte+Colony-stimulating+Factor&rank=15 Accessed 7/25/2012.
Cole GM, et al. “NSAID and Antioxidant Prevention of Alzheimer’s Disease: Lessons from in Vitro and Animal Models.” Ann N Y Acad Sci. 1035 (2004): 68-84.
Colomina MT and Peris-Sampedro F. Aluminum and Alzheimer's Disease. Adv Neurobiol. 2017;18: 183-197.
Corrêa HdL, Raab ATO, Araújo TM, et al. A systematic review and meta-analysis demonstrating Klotho as an emerging exerkine. Scientific Reports. 2022;12(1):17587. doi:10.1038/s41598-022-22123-1. https://pubmed.ncbi.nlm.nih.gov/36266389/
Corsonello A, et al. “Serum Magnesium Levels and Cognitive Impairment in Hospitalized Hypertensive Patients.” Magnes Res. 14.4 (2001): 273-82.
Cotman CW, et al. “Exercise Builds Brain Health: Key Roles of Growth Factor Cascades and Inflammation.” Trends Neurosci. 30.9 (2007): 464-72.
Crack PJ, et al. Lack of Glutathione Peroxidase-1 Exacerbates Abeta-Mediated Neurotoxicity in Cortical Neurons.” J Neural Transm 113.5 (2006): 645-57. Epub ahead of print October 21, 2005.
Creeley CE, et al. “Donepezil Markedly Potentiates Memantine Neurotoxicity in the Adult Rat Brain.” Neurobiol Aging. 29.2 (2008): 153-67.
Crespo-Biel N, Theunis C, and Van Leuven F. Protein tau: prime cause of synaptic and neuronal degeneration in Alzheimer's disease. Int J Alzheimers Dis. 2012;2012:251426.
Culpan d, Kehoe PG, Love S. “Tumor necrosis factor-α (TNF-α) and miRNA expression in frontal and temporal neocortex in Alzheimer’s disease and the effect of TNFα on miRNA expression in vitro.” Int J Mol Epidemiol Genet. 2.2 (2011): 156-62.
Cummings J, Osse AML, Cammann D, Powell J, Chen J. Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. Jan 2024;38(1):5-22. doi:10.1007/s40259-023-00633-2. https://pubmed.ncbi.nlm.nih.gov/37955845/
Damiano RF, Loureiro JC, Pais MV, et al. Revisiting global cognitive and functional state 13 years after a clinical trial of lithium for mild cognitive impairment. Braz J Psychiatry. Mar 11 2023;45(1):46-49. doi:10.47626/1516-4446-2022-2767. https://www.ncbi.nlm.nih.gov/pubmed/36049127
Danysz W, Parsons CG. “Alzheimer′s disease, β-amyloid, glutamate, NMDA receptors and memantine – searching for the connections.” Br J Pharmacol. 2012 May 30. doi: 10.1111/j.1476-5381.2012.02057.x. [Epub ahead of print]
Daviglus ML, et al. “Risk Factors and Preventive Interventions for Alzheimer’s disease: State of the Science.” Arch Neurol. 68.9 (2011): 1185-90.
de Jong DLK, de Heus RAA, Rijpma A, et al. Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease. Hypertension. 2019 Aug;74(2):413-420.
de la Monte SM. Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease. Drugs. 2017;77(1): 47-65.
de la Monte SM, et al. The 20-Year Voyage Aboard the Journal of Alzheimer's Disease: Docking at 'Type 3 Diabetes', Environmental/Exposure Factors, Pathogenic Mechanisms, and Potential Treatments. J Alzheimers Dis. 2018;62(3): 1381-1390.
Deleglise B, Lassus B, Soubeyre V, et al. Synapto-protective drugs evaluation in reconstructed neuronal network. PloS one.2013;8(8):e71103.
Delumeau JC, Bentue-Ferrer D, Gandon JM, Amrein R, Belliard S, Allain H. Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases. Journal of neural transmission. Supplementum.1994;41:259-266.
Demarin V, Podobnik SS, Storga-Tomic D, Kay G. Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study. Drugs under experimental and clinical research.2004;30(1):27-33.
De-Paula VJR, Radanovic M, Forlenza OV. Lithium and neuroprotection: a review of molecular targets and biological effects at subtherapeutic concentrations in preclinical models of Alzheimer's disease. International journal of bipolar disorders. May 10 2025;13(1):16. doi:10.1186/s40345-025-00386-7. https://www.ncbi.nlm.nih.gov/pubmed/40348943
Devanand DP, Crocco E, Forester BP, et al. Low Dose Lithium Treatment of Behavioral Complications in Alzheimer's Disease: Lit-AD Randomized Clinical Trial. Am J Geriatr Psychiatry. Jan 2022;30(1):32-42. doi:10.1016/j.jagp.2021.04.014. https://www.ncbi.nlm.nih.gov/pubmed/34059401
Devarakonda SS, Basha S, Pithakumar A, et al. Molecular mechanisms of neurofilament alterations and its application in assessing neurodegenerative disorders. Ageing Res Rev. 2024;102:102566. doi:10.1016/j.arr.2024.102566. https://pubmed.ncbi.nlm.nih.gov/39481763/
Dézsi L, et al. “Neuroprotective Effects of Vinpocetine in Vivo and in Vitro: Apovincaminic Acid Derivatives as Potential Therapeutic Tools in Ischemic Stroke” [in Hungarian]. Acta Pharm Hung. 72.2 (2002): 84-91.
Dhanasekaran M, et al. “The Emerging Role of Coenzyme Q-10 in Aging, Neurodegeneration, Cardiovascular Disease, Cancer and Diabetes Mellitus.” Curr Neurovasc Res. 2.5 (2005): 447-59.
Dhitavat S, et al. “Folate, Vitamin E, and Acetyl-L-Carnitine Provide Synergistic Protection against Oxidative Stress Resulting from Exposure of Human Neuroblastoma Cells to Amyloid-Beta.” Brain Res. 1061.2 (2005): 114-7.
Diamond BJ, et al. “Ginkgo biloba Extract: Mechanisms and Clinical Indications.” Arch Phys Med Rehab. 81.5 (2000): 668-78.
Dimpfel W, Storni C, Verbruggen M. Ingested oat herb extract (Avena sativa) changes EEG spectral frequencies in healthy subjects. Journal of alternative and complementary medicine.May 2011;17(5):427-434.
Di Meco A, Lauretti E, Vagnozzi AN, Pratico D. Zileuton restores memory impairments and reverses amyloid and tau pathology in aged Alzheimer's disease mice. Neurobiology of aging. Nov 2014;35(11):2458-2464.
Dominguez LJ, Veronese N, Parisi A, et al. Mediterranean Diet and Lifestyle in Persons with Mild to Moderate Alzheimer's Disease. Nutrients. Oct 9 2024;16(19)doi:10.3390/nu16193421. https://pubmed.ncbi.nlm.nih.gov/39408386/
Dominy S, Lynch C, Ermini F et al. Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv. 2019;5(1):eaau3333.
Dong-gyu J, et al. “Evidence That γ-Secretase Mediates Oxidative-Stress Induced β-Secretase Expression in Alzheimer’s disease.” Neurobiol Aging. 2010 Jun;31(6):917-25.
Douraghi-Zadeh D, Matharu B, Razvi A, Austen B. The protective effects of the nutraceutical, colostrinin, against Alzheimer's disease, is mediated via prevention of apoptosis in human neurones induced by aggregated beta-amyloid. The journal of nutrition, health & aging.Jun 2009;13(6):522-527.
Dubal DB, Zhu L, Sanchez PE, et al. Life Extension Factor Klotho Prevents Mortality and Enhances Cognition in hAPP Transgenic Mice. The Journal of Neuroscience. 2015;35(6):2358. doi:10.1523/JNEUROSCI.5791-12.2015. https://pubmed.ncbi.nlm.nih.gov/25673831/
Dubois B, Villain N, Schneider L. Alzheimer Disease as a Clinical-Biological Construct–An International Working Group Recommendation. JAMA Neurol. 2024;81(12):1304-1311. doi:10.1001/jamaneurol.2024.3770. https://pubmed.ncbi.nlm.nih.gov/39483064/
Dyer O. Aduhelm: Biogen abandons Alzheimer's drug after controversial approval left it unfunded by Medicare. BMJ. Feb 2 2024;384:q281. doi:10.1136/bmj.q281. https://pubmed.ncbi.nlm.nih.gov/38307520/
Ebell MH, Barry HC, Baduni K, Grasso G. Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis. Ann Fam Med. Jan-Feb 2024;22(1):50-62. doi:10.1370/afm.3050. https://pubmed.ncbi.nlm.nih.gov/38253509/
Eimer WA, Vijaya Kumar DK, Navalpur Shanmugam NK, et al. Alzheimer's Disease-Associated β-Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain Infection. Neuron. Jul 11 2018;99(1):56-63.e3. doi:10.1016/j.neuron.2018.06.030.
Ejaz P, Bhojani K, Joshi VR. NSAIDs and kidney. J Assoc Physicians India. 2004 Aug;52:632-40.
Engelborghs S, et al. “Correlations between Cognitive, Behavioural and Psychological Findings and Levels of Vitamin B12 and Folate in Patients with Dementia.” Int J Geriatr Psychiatry. 19.4 (2004): 365-70.
Engelborghs S, Le Bastard N. “The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer’s disease.” Mol Diagn Ther. 16.3 (2012): 135-41.
Epis R, et al. “Modulatory Effect of Acetyl-L-Carnitine on Amyloid Precursor Protein Metabolism in Hippocampal Neurons.” Eur J Pharmocol. 597.1-3 (2008): 51-53.
Eyles DW, et al. “Distribution of the Vitamin D Receptor and 1α-hydroxylase in Human Brain.” J Chem Neuroanat. 29.1 (2005): 21-30.
Eyting M, Xie M, Heß S, Heß S, Geldsetzer P. Causal evidence that herpes zoster vaccination prevents a proportion of dementia cases. medRxiv. May 25 2023;doi:10.1101/2023.05.23.23290253.
Facecchia K, et al. “Oxidative Toxicity in Neurodegenerative Diseases: Role of Mitochondrial Dysfunction and Therapeutic Strategies.” J Toxicol. 2011 (2011): 683728. Epub ahead of print July 14, 2011.
Fajardo VA, Fajardo VA, LeBlanc PJ, MacPherson REK. Examining the Relationship between Trace Lithium in Drinking Water and the Rising Rates of Age-Adjusted Alzheimer's Disease Mortality in Texas. J Alzheimers Dis. 2018;61(1):425-434. doi:10.3233/JAD-170744. https://www.ncbi.nlm.nih.gov/pubmed/29103043
Farr SA, et al. “DHEAS Improves Learning and Memory in Aged SAMP8 Mice but Not in Diabetic Mice.” Life Sci. 75.2 (2004): 2775-85.
Feart C, Letenneur L, Helmer C, et al. Plasma Carotenoids Are Inversely Associated With Dementia Risk in an Elderly French Cohort. The journals of gerontology Series A, Biological sciences and medical sciences. 2016;71(5):683-688.
Fenton L, Isenberg AL, Aslanyan V, et al. Variability in objective sleep is associated with Alzheimer's pathology and cognition. Brain Commun. 2023;5(2): fcad031. https://pubmed.ncbi.nlm.nih.gov/36895954/
Ferensztajn-Rochowiak E and Rybakowski JK. The effect of lithium on hematopoietic, mesenchymal and neural stem cells. Pharmacol Rep. 2016;68(2): 224-230.
Finali G, Piccirilli M, Oliani C, Piccinin GL. L-deprenyl therapy improves verbal memory in amnesic Alzheimer patients. Clinical neuropharmacology.Dec 1991;14(6):523-536.
Fleisher AS, et al. “Phase 2 Safety Trial Targeting Amyloid Beta Production with a Gamma-Secretase Inhibitor in Alzheimer Disease.” Arch Neurol. 65.8 (2008): 1031-8.
Foley KE, Wilcock DM. Three major effects of APOE(ε4) on Aβ immunotherapy induced ARIA. Front Aging Neurosci. 2024;16:1412006. doi:10.3389/fnagi.2024.1412006. https://pubmed.ncbi.nlm.nih.gov/38756535/
Fonte V, Dostal V, Roberts CM et al. A glycine zipper motif mediates the formation of toxic β-amyloid oligomers in vitro and in vivo. Mol Neurodegener. 2011 Aug 23;6(1):61.
Food and Drug Administration (FDA). Drugs page. Drugs to be Discontinued. Available at: http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050794.htm. Last updated 5/28/2013. Accessed 5/28/2013.
Forette F, et al. “Prevention of Dementia in Randomised Double-Blind Placebo-Controlled Systolic Hypertension in Europe (Syst-Eur) Trial.” Lancet. 352.9137 (1998): 1347-51.
Forlenza OV, Radanovic M, Talib LL, Gattaz WF. Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial. Br J Psychiatry. Nov 2019;215(5):668-674. doi:10.1192/bjp.2019.76. https://www.ncbi.nlm.nih.gov/pubmed/30947755
Forman HJ, et al. “Glutathione: Overview of its Protective Roles, Measurement, and Biosynthesis.” Mol Aspects Med. 30.1-2 (2009): 1-12.
Galbusera C, et al. “Increased Susceptibility to Plasma Lipid Peroxidation in Alzheimer Disease Patients.” Curr Alzheimer Res. 1.2 (2004): 103-9.
Gale SA. Language and Meaning: Asymptomatic Alzheimer's Disease in the Clinic and Society. J Alzheimers Dis. 2024;99(2):489-492. doi:10.3233/jad-240195. https://pubmed.ncbi.nlm.nih.gov/38701152/
Galpern WR, et al. “Coenzyme Q Treatment of Neurodegenerative Diseases of Aging.” Mitochondrion. 7 Supp (2007): S146-53.
Gao J, Wang WY, Mao YW, et al. A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature.Aug 26 2010;466(7310):1105-1109.
Garcia-Revilla J, Boza-Serrano A, Espinosa-Oliva AM, et al. Galectin-3, a rising star in modulating microglia activation under conditions of neurodegeneration. Cell Death Dis. Jul 20 2022;13(7):628. doi:10.1038/s41419-022-05058-3. https://pubmed.ncbi.nlm.nih.gov/35859075/
Gauthier S, et al. “Can We Do Better in Developing New Drugs for Alzheimer’s Disease?” Alzheimers Dement. 5.6 (2009): 489-91.
Geda Y, et al. “Caloric Intake, Aging, and Mild Cognitive Impairment: A Population-Based Study.” Presented at the 64th Annual Meeting of the American Academy of Neurology. New Orleans. April 21-28, 2012.
Giannopoulos PF, Chu J, Joshi YB, Sperow M, Li JG, Kirby LG, Pratico D. Gene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple-transgenic model of Alzheimer's disease. Molecular psychiatry. Apr 2014;19(4):511-518.
Giannopoulos PF, Chiu J, Pratico D. Antileukotriene therapy by reducing tau phosphorylation improves synaptic integrity and cognition of P301S transgenic mice. Aging cell. Jun 2018a;17(3):e12759.
Giannopoulos PF, Chiu J, Pratico D. Learning Impairments, Memory Deficits, and Neuropathology in Aged Tau Transgenic Mice Are Dependent on Leukotrienes Biosynthesis: Role of the cdk5 Kinase Pathway. Molecular neurobiology. Jun 7 2018b.
Gibson GE, et al. Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial. J Alzheimers Dis. 2020;78(3): 989-1010.
Gehin A, et al. “Glyphosate-induced Antioxidant Imbalance in HaCaT: The Protective Effect of Vitamins C and E.” Environ Toxicol Pharmocol. 22.1 (2006): 27-34.
Godhia ML, Patel N. Colostrum–its Composition, Benefits as a Nutraceutical–A Review. Current Research in Nutrition and Food Science Journal.2013;1(1):37-47.
Gomez-Pinilla F, et al. “Brain-Derived Neurotrophic Factor Functions as a Metabotrophin to Mediate the Effects of Exercise on Cognition.” Eur J Neurosci. 28.11 (2008): 2278-87.
Gong B, Pan Y, Vempati P, et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol Aging.Jun 2013;34(6):1581-1588.
Grant WB. Using Multicountry Ecological and Observational Studies to Determine Dietary Risk Factors for Alzheimer's Disease. J Am Coll Nutr. Jul 2016;35(5):476-89. doi:10.1080/07315724.2016.1161566. https://pubmed.ncbi.nlm.nih.gov/27454859/
Grimmig B, Kim SH, Nash K, Bickford PC, Douglas Shytle R. Neuroprotective mechanisms of astaxanthin: a potential therapeutic role in preserving cognitive function in age and neurodegeneration. GeroScience. Feb 2017;39(1):19-32.
Grundman M. “Vitamin E and Alzheimer Disease: The Basis for Additional Clinical Trials.” Am J Clin Nutr. 71.2 (2000): 630S-6S.
Grzybowski A, Barboni P. OCT and Imaging in Central Nervous System Diseases: The Eye as a Window to the Brain. Springer Nature; 2020.
Gu X, Qi L, Qi Q, Zhou J, Chen S, Wang L. Monoclonal antibody therapy for Alzheimer's disease focusing on intracerebral targets. Bioscience trends. Mar 19 2024;18(1):49-65. doi:10.5582/bst.2023.01288. https://pubmed.ncbi.nlm.nih.gov/38382942/
Guedes AC, Amaro HM, Malcata FX. Microalgae as sources of carotenoids. Marine drugs. 2011;9(4):625-644.
Gutzmann H, and Hadler D. Sustained Efficacy and Safety of Idebenone in the Treatment of Alzheimer's Disease: Update on a 2-Year Double-Blind Multicentre Study. [In eng] J Neural Transm Suppl. 1998 54(301-10.
Gutzmann H, Kuhl KP, Hadler D, et al. Safety and Efficacy of Idebenone Versus Tacrine in Patients with Alzheimer's Disease: Results of a Randomized, Double-Blind, Parallel-Group Multicenter Study. [In eng] Pharmacopsychiatry. 2002 Jan; 35(1): 12-8.
Hager K, et al. “Alpha-Lipoic Acid as a New Treatment Option for Alzheimer [corrected] Type Dementia.” Arch Gerontol Geriatr. 32.3 (2001): 275-82.
Hager K, et al. “Alpha-Lipoic Acid as a New Treatment Option for Alzheimer's Disease—A 48 Months Follow-up Analysis.” J Neural Transm Suppl. 72 (2007): 189-93.
Hajjar IM, et al. “Angiotensin Converting Enzyme Inhibitors and Cognitive and Functional Decline in Patients with Alzheimer’s Disease: An Observational Study.” Am J Alzheimers Dis Other Demen. 23.1 (2008): 77-83.
Halmos T and Suba I. [Alzheimer's disease and diabetes - the common pathogenesis]. Neuropsychopharmacol Hung. 2016;18(1): 5-19.
Hampel H, Prvulovic D, Teipel S, et al. The future of Alzheimer's disease: the next 10 years. Prog Neurobiol. 2011 Dec;95(4):718-28.
Han JH, Lee YS, Im JH, et al. Astaxanthin Ameliorates Lipopolysaccharide-Induced Neuroinflammation, Oxidative Stress and Memory Dysfunction through Inactivation of the Signal Transducer and Activator of Transcription 3 Pathway. Mar Drugs. 2019;17(2).
Hansen RA, et al. “Efficacy and Safety of Donepezil, Galantamine, and Rivastigmine for the Treatment of Alzheimer’s Disease: A Systematic Review and Meta-Analysis.” Clin Interv Aging. 3.2 (2008): 211-25.
Hansson O, Blennow K, Zetterberg H, Dage J. Blood biomarkers for Alzheimer's disease in clinical practice and trials. Nat Aging. 2023;3(5):506-519. doi:10.1038/s43587-023-00403-3. https://pubmed.ncbi.nlm.nih.gov/37202517/
Haque AM, et al. “Green Tea Catechins Prevent Cognitive Deficits Caused by Abeta1-40 in Rats.” J Nutr Biochem. 19.9 (2008): 619-26.
Harris E. FDA Green-Lights Second Alzheimer Drug, Donanemab. Jama. Aug 20 2024;332(7):524. doi:10.1001/jama.2024.13386. https://pubmed.ncbi.nlm.nih.gov/39058481/
Harrison FE. “A critical review of vitamin C for the prevention of age-related cognitive decline and Alzheimer’s disease.” J Alzheimer’s Dis. 29.4 (2012): 711-26.
Haskell CF, et al. “Effects of a Multi-Vitamin/Mineral Supplement on Cognitive Function and Fatigue During Extended Multi-Tasking.” Hum Psychopharmacol. 25.6 (2010): 448-61.
Hayden K. M., Zandi P. P., Khachaturian A. S., et al. Cache County Investigators (2007). Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology 69, 275–282.
Hazan J, Liu KY, Costello H, Isaacs JD, Thambisetty M, Howard R. Challenges in a Biological Definition of Alzheimer Disease. Neurology. 2024;103(9):e209884. doi:10.1212/wnl.0000000000209884. https://pubmed.ncbi.nlm.nih.gov/39353147/
Hedi H, Norbert G. 5-Lipoxygenase Pathway, Dendritic Cells, and Adaptive Immunity. Journal of biomedicine & biotechnology. 2004;2004(2):99-105.
Hendrix SB, Soininen H, Solomon A, et al. Combined Evidence for a Long-Term, Clinical Slowing Effect of Multinutrient Intervention in Prodromal Alzheimer's Disease: Post-Hoc Analysis of 3-Year Data from the LipiDiDiet Trial. The journal of prevention of Alzheimer's disease. 2023;10(3):464-470. doi:10.14283/jpad.2023.29. https://pubmed.ncbi.nlm.nih.gov/37357286/
Hillen T, et al. “DHEA-S Plasma Levels and Incidence of Alzheimer’s Disease.” Biol Psychiatry. 47.2 (2000): 161-3.
Hinterberger M and Fischer P. “Folate and Alzheimer: when time matters.” J Neural Transm. 2012 May 25. [Epub ahead of print]
Ho L, et al. “Heterogeneity in Red Wine Polyphenolic Contents Differentially Influences Alzheimer’s Disease-Type Neuropathology and Cognitive Deterioration.” J Alzheimers Dis. 16.1 (2009): 59-72.
Høilund-Carlsen PF, Alavi A, Barrio JR. PET/CT/MRI in Clinical Trials of Alzheimer's Disease. J Alzheimers Dis. 2024;101(s1):S579-s601. doi:10.3233/jad-240206. https://pubmed.ncbi.nlm.nih.gov/39422954/
Holmes C, et al. “Long-Term Effects of Abeta42 Immunisation in Alzheimer’s Disease: Follow-Up of a Randomised, Placebo-Controlled Phase I Trial.” Lancet. 2008 Jul 19;372(9634):216-23.
Holmquist L, et al. “Lipoic Acid as a Novel Treatment for Alzheimer’s disease and Related Dementias.” Pharmacol Thera. 113.1 (2007): 154-164.
Hong X, Huang L, Lei F, et al. The Role and Pathogenesis of Tau Protein in Alzheimer's Disease. Biomolecules. 2025;15(6)doi:10.3390/biom15060824. https://pubmed.ncbi.nlm.nih.gov/40563464/
Hongo N, Takamura Y, Nishimaru H, et al. Astaxanthin Ameliorated Parvalbumin-Positive Neuron Deficits and Alzheimer's Disease-Related Pathological Progression in the Hippocampus of App(NL-G-F/NL-G-F) Mice. Frontiers in pharmacology. 2020;11:307.
Honjo K, van Reekum R, Verhoeff NP. Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease? Alzheimers Dement. 2009 Jul;5(4):348-60.
Horie K, Salvadó G, Koppisetti RK, et al. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease. Nat Med. 2025;31(6):2044-2053. doi:10.1038/s41591-025-03617-7. https://pubmed.ncbi.nlm.nih.gov/40164726/
Houtkooper RH, Canto C, Wanders RJ, Auwerx J. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev. Apr 2010;31(2):194-223.
Huang Q, Ma XQ, Chen HF. Lithium Exposure and Risk of Major Neurocognitive Disorders: A Systematic Review and Meta-analysis. Journal of clinical psychopharmacology. Jul-Aug 01 2024;44(4):418-423. doi:10.1097/JCP.0000000000001863. https://www.ncbi.nlm.nih.gov/pubmed/38743015
Huat TJ, et al. Metal Toxicity Links to Alzheimer's Disease and Neuroinflammation. J Mol Biol. 2019;431(9): 1843-1868.
Iguacel I, Huybrechts I, Moreno LA, Michels N. Vegetarianism and veganism compared with mental health and cognitive outcomes: a systematic review and meta-analysis. Nutr Rev. Mar 9 2021;79(4):361-381. doi:10.1093/nutrit/nuaa030. https://pubmed.ncbi.nlm.nih.gov/32483598/
Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol.Aug 2014;24(8):464-471.
Ishii N, Terao T, Hirakawa H. The Present State of Lithium for the Prevention of Dementia Related to Alzheimer's Dementia in Clinical and Epidemiological Studies: A Critical Review. International journal of environmental research and public health. Jul 22 2021;18(15)doi:10.3390/ijerph18157756. https://www.ncbi.nlm.nih.gov/pubmed/34360049
Israel E, Cohn J, Dube L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. Jama. Mar 27 1996;275(12):931-936.
Ito N, Saito H, Seki S, Ueda F, Asada T. Effects of Composite Supplement Containing Astaxanthin and Sesamin on Cognitive Functions in People with Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial. J Alzheimers Dis. 2018;62(4):1767-1775.
Ito S, et al. “1-alpha,25-Dihydroxyvitamin D3 Enhances Cerebral Clearance of Human Amyloid-Β Peptide(1-40) from Mouse Brain across the Blood-Brain Barrier.” Fluids Barriers CNS. 8 (2011): 20.
Ittner LM and Götz J. Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci. 2011 Feb;12(2):65-72.
Jack CR, Jr., Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2024;20(8):5143-5169. doi:10.1002/alz.13859. https://pubmed.ncbi.nlm.nih.gov/38934362/
Jack CR, Jr., Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018. https://pubmed.ncbi.nlm.nih.gov/29653606/
Jack CR, Jr., Therneau TM, Weigand SD, et al. Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework. JAMA Neurol. 2019;76(10):1174-1183. doi:10.1001/jamaneurol.2019.1971. https://pubmed.ncbi.nlm.nih.gov/31305929/
Jaiswal R, et al. “Profile and characterization of the chlorogenic acids in green Robusta coffee beans by LC-MS(n): identification of seven new classes of compounds.” J Agric Food Chem. 58.15 (2010): 8722-37.
Janssen IM, et al. “Ginkgo biloba in Alzheimer’s Disease: A Systematic Review.” Wien Med Wochenschr. 160.21-22 (2010): 539-46.
Janusz M, Woszczyna M, Lisowski M, Kubis A, Macala J, Gotszalk T, Lisowski J. Ovine colostrum nanopeptide affects amyloid beta aggregation. FEBS letters.Jan 05 2009;583(1):190-196.
Janusz M, Zablocka A. Colostral proline-rich polypeptides--immunoregulatory properties and prospects of therapeutic use in Alzheimer's disease. Current Alzheimer research.Jun 2010;7(4):323-333.
Janusz M, Zablocka A. Colostrinin: a proline-rich polypeptide complex of potential therapeutic interest. Cellular and molecular biology (Noisy-le-Grand, France).Nov 03 2013;59(1):4-11.
Ji X, Peng D, Zhang Y, Zhang J, Wang Y, Gao Y, . . . Tang P. Astaxanthin improves cognitive performance in mice following mild traumatic brain injury. Brain research. Mar 15 2017;1659:88-95.
Jiang H, et al. “Granulocyte Colony-Stimulating Factor Attenuates Chronic Neuroinflammation in the Brain of Amyloid Precursor Protein Transgenic Mice: An Alzheimer’s Disease Mouse Model.” J Int Med Res. 38.4 (2010): 1305-12.
Johns Hopkins Medicine. Early-Onset Alzheimer’s Disease. 2025. Accessed 07/03/2025. https://www.hopkinsmedicine.org/health/conditions-and-diseases/alzheimers-disease/earlyonset-alzheimer-disease
Joshi YB, Pratico D. The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer's disease phenotype. Frontiers in cellular neuroscience. 2014;8:436.
Jossan SS, Gillberg PG, Gottfries CG, Karlsson I, Oreland L. Monoamine oxidase B in brains from patients with Alzheimer's disease: a biochemical and autoradiographical study. Neuroscience.1991;45(1):1-12.
Jóźwiak S, et al. “Dietary Treatment of Epilepsy: Rebirth of an Ancient Treatment.” Neurol Neurochir Pol. 45.4 (2011): 370-8.
Kado DM, et al. “Homocysteine versus the Vitamins Folate, B6, and B12 as Predictors of Cognitive Function and Decline in Older High-Functioning Adults: MacArthur Studies of Successful Aging.” Am J Med. 118.2 (2005): 161-7.
Kalaria RN, Akinyemi R, and Ihara M. Does Vascular Pathology Contribute to Alzheimer Changes? [In Eng] J Neurol Sci. 2012 Aug 9;
Kamer AR, et al. Periodontal dysbiosis associates with reduced CSF Aβ42 in cognitively normal elderly. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2021;13(1): e12172.
Kanbay M, Copur S, Ozbek L, et al. Klotho: a potential therapeutic target in aging and neurodegeneration beyond chronic kidney disease-a comprehensive review from the ERA CKD-MBD working group. Clin Kidney J. Jan 2024;17(1):sfad276. doi:10.1093/ckj/sfad276. https://pubmed.ncbi.nlm.nih.gov/38213484/
Kariv-Inbal Z, Yacobson S, Berkecz R, et al. The isoform-specific pathological effects of apoE4 in vivo are prevented by a fish oil (DHA) diet and are modified by cholesterol. J Alzheimers Dis. 2012;28(3):667-83.
Karl TB, et al. The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's disease. Behav Pharmacol. 2017;28(2 and 3-Spec Issue): 142-160.
Katagiri M, Satoh A, Tsuji S, Shirasawa T. Effects of astaxanthin-rich Haematococcus pluvialis extract on cognitive function: a randomised, double-blind, placebo-controlled study. Journal of clinical biochemistry and nutrition. Sep 2012;51(2):102-107.
Kato-Kataoka A, et al. “Soybean-derived Phosphatidylserine Improves Memory Functions of the Elderly Japanese Subjects with Memory Complaints.” J Clin Biochem Nutr. 47.3 (2010) 246-55.
Katonova A, Sheardova K, Amlerova J, Angelucci F, Hort J. Effect of a Vegan Diet on Alzheimer's Disease. Int J Mol Sci. Nov 29 2022;23(23)doi:10.3390/ijms232314924. https://pubmed.ncbi.nlm.nih.gov/36499257/
Kellar D and Craft S. Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches. Lancet Neurol. 2020;19(9): 758-766.
Kelly D, Coen RF, Akuffo KO, et al. Cognitive Function and Its Relationship with Macular Pigment Optical Density and Serum Concentrations of its Constituent Carotenoids. J Alzheimers Dis. 2015;48(1):261-277.
Kelley BJ, Petersen RC. Alzheimer's disease and mild cognitive impairment. Neurologic clinics. Aug 2007;25(3):577-609, v.
Kennedy DO, et al. “Acute Cognitive Effects of Standardised Ginkgo Biloba Extract Complexed with Phosphatidylserine.” Hum Psychopharmacol. 22.4 (2007): 199-210.
Kennedy DO, et al. “Dose Dependent Changes in Cognitive Performance and Mood Following Acute Administration of Ginseng to Healthy Young Volunteers.” Nutr Neurosci. 4.4 (2001): 295-310.
Kennedy DO, Jackson PA, Forster J, Khan J, Grothe T, Perrinjaquet-Moccetti T, Haskell-Ramsay CF. Acute effects of a wild green-oat (Avena sativa) extract on cognitive function in middle-aged adults: A double-blind, placebo-controlled, within-subjects trial. Nutritional neuroscience.Nov 30 2015.
Kessing LV, Gerds TA, Knudsen NN, et al. Association of Lithium in Drinking Water With the Incidence of Dementia. JAMA Psychiatry. 2017;74(10):1005-1010. doi:10.1001/jamapsychiatry.2017.2362. https://dx.doi.org/10.1001/jamapsychiatry.2017.2362
Khan MA, Tania M, Liu R, Rahman MM. Hericium erinaceus: an edible mushroom with medicinal values. Journal of complementary & integrative medicine. May 24 2013;10.
Khodadadi HL, et al. Cannabidiol Ameliorates Cognitive Function via Regulation of IL-33 and TREM2 Upregulation in a Murine Model of Alzheimer's Disease. J Alzheimers Dis. 2021;80(3): 973-977.
Kidd PM. “Neurodegeneration from Mitochondrial Insufficiency: Nutrients, Stem Cells, Growth Factors, and Prospects for Brain Rebuilding Using Integrative Management.” Altern Med Rev. 10.4 (2005): 268-93.
Kim D, et al. “SIRT1 Deacetylase Protects against Neurodegeneration in Models for Alzheimer’s Disease and Amyotrophic Lateral Sclerosis.” EMBO J. 26.13 (2007): 3169-79.
Kim J, et al. Holtzman. Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Abeta amyloidosis. J Exp Med. 2012;209(12): 2149-2156.
Kim J, et al. “The Inhibitory Effect of Pyrroloquinoline Quinone on the Amyloid Formation and Cytotoxicity of Truncated Alpha-Synuclein.” Mol Neurodegener. 5 (2010): 20.
Kim TI, et al. “L-Theanine, an Amino Acid in Green Tea, Attenuates Beta-Amyloid-Induced Cognitive Dysfunction and Neurotoxicity: Reduction in Oxidative Damage and Inactivation of ERK/p38 Kinase and NF-kappaB Pathways.” Free Radic Biol Med. 47.11 (2009): 1601-10.
King MK, et al. Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments. Pharmacol Ther. 2014;141(1): 1-12.
Kivipelto M, Mangialasche F, Snyder HM, et al. World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia. Alzheimers Dement. Jul 2020;16(7):1078-1094. doi:10.1002/alz.12123. https://pubmed.ncbi.nlm.nih.gov/32627328/
Klafki H-W, Morgado B, Wirths O, et al. Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40? Fluids and Barriers of the CNS. 2022;19(1):96. doi:10.1186/s12987-022-00390-4. https://pubmed.ncbi.nlm.nih.gov/36461122/
Knopman DS. Alzheimer’s Disease and Other Dementias. In: Goldman L, Schafer AI. Goldman’s Cecil Medicine. 24th ed. Philadelphia, PA:Elsevier;2012. Available at: http://www.mdconsult.com/books/page.do?eid=4-u1.0-B978-1-4377-1604-7..00409-7&isbn=978-1-4377-1604-7&uniqId=349213967-58#4-u1.0-B978-1-4377-1604-7..00409-7--s0010. Accessed August 3, 2012.
Kuboyama T, et al. “Neuritic Regeneration and Synaptic Reconstruction Induced by Withanolide A.” Br J Pharmacol. 144.7 (2005): 961-71.
Kundu P, Zimmerman B, Quinn JF, et al. Serum Levels of α-Klotho Are Correlated with Cerebrospinal Fluid Levels and Predict Measures of Cognitive Function. J Alzheimers Dis. 2022;86(3):1471-1481. doi:10.3233/jad-215719. https://pubmed.ncbi.nlm.nih.gov/35213382/
Kuriyama N, Ozaki E, Mizuno T, et al. Association between α-Klotho and Deep White Matter Lesions in the Brain: A Pilot Case Control Study Using Brain MRI. Journal of Alzheimer's Disease. 2018;61:145-155. doi:10.3233/JAD-170466. https://pubmed.ncbi.nlm.nih.gov/29154273/
Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390(6655):45-51. doi:10.1038/36285. https://pubmed.ncbi.nlm.nih.gov/9363890/
Kurosu H, Yamamoto M, Clark JD, et al. Suppression of aging in mice by the hormone Klotho. Science. Sep 16 2005;309(5742):1829-33. doi:10.1126/science.1112766. https://pubmed.ncbi.nlm.nih.gov/16123266/
Kusoro O, Roche M, Del-Pino-Casado R, Leung P, Orgeta V. Time to Diagnosis in Dementia: A Systematic Review With Meta-Analysis. Int J Geriatr Psychiatry. 2025;40(7):e70129. doi:10.1002/gps.70129. https://pubmed.ncbi.nlm.nih.gov/40716451/
Kwon SH, et al. “Neuroprotective Effects of Chlorogenic Acid on Scopolamine-Induced Amnesia via Anti-Acetylcholinesterase and Anti-Oxidative Activities in Mice.” Eur J Pharmacol. 649.1-3 (2010): 210-7.
Laake K, Oeksengaard AR. D-cycloserine for Alzheimer's disease. The Cochrane database of systematic reviews. 2002(2):Cd003153.
LabCorp. Lumipulse pTau-217/Beta Amyloid 42 Ratio. 2025. Accessed 07/2025. https://www.labcorp.com/treatment-areas/neurology/clinical-testing/ptau217betaamyloid42ratio
Ladiwala ARA, et al. “Resveratrol Selectively Remodels Soluble Oligomers and Fibrils of Amyloid Beta into Off-Pathway Conformers.” J Biol Chem. 285 (2010): 24228-37.
Lakey-Beitia J, Kumar DJ, Hegde ML, Rao KS. Carotenoids as Novel Therapeutic Molecules Against Neurodegenerative Disorders: Chemistry and Molecular Docking Analysis. International journal of molecular sciences. 2019;20(22).
Landmark K. “Could Intake of Vitamins C and E Inhibit Development of Alzheimer Dementia?” [in Norwegian]. Tidsskr Nor Laegeforen. 126.2 (2006): 159-61.
Laske C, et al. “Decreased Plasma Levels of Granulocyte-Colony Stimulating Factor (G-CSF) in Patients with Early Alzheimer’s Disease.” J Alzheimers Dis. 17.1 (2009): 115-23.
Lau FC, et al. “The Beneficial Effects of Fruit Polyphenols on Brain Aging.” Neurobiol Aging. 26.1 (2005): 128-32.
Lee EH, Kim GH, Park HK, et al. Effects of the multidomain intervention with nutritional supplements on cognition and gut microbiome in early symptomatic Alzheimer's disease: a randomized controlled trial. Front Aging Neurosci. 2023;15:1266955. doi:10.3389/fnagi.2023.1266955. https://pubmed.ncbi.nlm.nih.gov/38020771/
Lee HJ, et al. Diabetes and Alzheimer's Disease: Mechanisms and Nutritional Aspects. Clinical nutrition research. 2018;7(4): 229-240.
Lee ST, et al. “Panax ginseng Enhances Cognitive Performance in Alzheimer Disease.” Alzheimer Dis Assoc Disord. 22.3 (2008): 222-6.
Lee YM, Han SI, Song BC, Yeum KJ. Bioactives in Commonly Consumed Cereal Grains: Implications for Oxidative Stress and Inflammation. Journal of medicinal food.Nov 2015;18(11):1179-1186.
Lehrer S, Rheinstein PH. Herpes Zoster Vaccination Reduces Risk of Dementia. In Vivo. Nov-Dec 2021;35(6):3271-3275. doi:10.21873/invivo.12622. https://iv.iiarjournals.org/content/invivo/35/6/3271.full.pdf
Lehrer S, Rheinstein PH. Vaccination Reduces Risk of Alzheimer's Disease, Parkinson's Disease and Other Neurodegenerative Disorders. Discovery medicine. Sep-Oct 2022;34(172):97-101.
Lehtisalo J, Rusanen M, Solomon A, et al. Effect of a multi-domain lifestyle intervention on cardiovascular risk in older people: the FINGER trial. Eur Heart J. Jun 1 2022;43(21):2054-2061. doi:10.1093/eurheartj/ehab922. https://pubmed.ncbi.nlm.nih.gov/35051281/
Leipp F, Vialaret J, Mohaupt P, et al. Glial fibrillary acidic protein in Alzheimer's disease: a narrative review. Brain Commun. 2024;6(6):fcae396. doi:10.1093/braincomms/fcae396. https://pubmed.ncbi.nlm.nih.gov/39554381/
Leszek J, Inglot AD, Janusz M, Byczkiewicz F, Kiejna A, Georgiades J, Lisowski J. Colostrinin proline-rich polypeptide complex from ovine colostrum--a long-term study of its efficacy in Alzheimer's disease. Medical science monitor: international medical journal of experimental and clinical research.Oct 2002;8(10):Pi93-96.
Leszek J, Inglot AD, Janusz M, Lisowski J, Krukowska K, Georgiades JA. Colostrinin: a proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Archivum immunologiae et therapiae experimentalis. 1999;47(6):377-385.
Leuner K, Müller WE, and Reichert AS. From Mitochondrial Dysfunction to Amyloid Beta Formation: Novel Insights into the Pathogenesis of Alzheimer's Disease. Mol Neurobiol. 2012 Jul 26. [Epub ahead of print]
Leuzy A, Bollack A, Pellegrino D, et al. Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2025;21(3):e14528. doi:10.1002/alz.14528. https://pubmed.ncbi.nlm.nih.gov/40042435/
Li G, et al. “Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor and Cognitive Function in Non-Demented Subjects.” PLoS One. 4.5 (2009): Epub ahead of print May 1, 2009.
Li H, et al. Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer's disease. Eur J Med Chem. 2020;192: 112163.
Li MH, et al. “Protective Effects of Oligomers of Grape Seed Polyphenols against Beta-Amyloid-Induced Oxidative Cell Death.” Ann NY Acad Sci. 1030 (2004): 317-29.
Li Q, Barres BA. Microglia and macrophages in brain homeostasis and disease. Nature Reviews Immunology. 2018;18(4):225-242. doi:10.1038/nri.2017.125. https://pubmed.ncbi.nlm.nih.gov/29151590/
Li X, Qi Z, Zhao L, Yu Z. Astaxanthin reduces type 2 diabeticassociated cognitive decline in rats via activation of PI3K/Akt and attenuation of oxidative stress. Molecular medicine reports. Jan 2016;13(1):973-979.
Li Y, Li Y, Gu X, et al. Long-Term Intake of Red Meat in Relation to Dementia Risk and Cognitive Function in US Adults. Neurology. Feb 11 2025;104(3):e210286. doi:10.1212/WNL.0000000000210286. https://pubmed.ncbi.nlm.nih.gov/39813632/
Lima VC, Rosen RB, Farah M. Macular pigment in retinal health and disease. Int J Retina Vitreous. 2016;2:19.
Linghui D, Simin Y, Zilong Z, Yuxiao L, Shi Q, Birong D. The relationship between serum klotho and cognitive performance in a nationally representative sample of US adults. Front Aging Neurosci. 2023;15:1053390. doi:10.3389/fnagi.2023.1053390. https://pubmed.ncbi.nlm.nih.gov/36819720/
Liu S, et al. “Enhanced Rat Sciatic Nerve Regeneration through Silicon Tubes Filled with Pyrroloquinoline Quinone.” Microsurgery. 25.4 (2005): 329-37.
Liu Y, Wang W, Li Y, Xiao Y, Cheng J, Jia J. The 5-Lipoxygenase Inhibitor Zileuton Confers Neuroprotection against Glutamate Oxidative Damage by Inhibiting Ferroptosis. Biological & pharmaceutical bulletin. 2015;38(8):1234-1239.
Lo D and Grossberg GT. Use of memantine for the treatment of dementia. Expert Rev Neurother. 2011 Oct;11(10):1359-70.
Loeb MB, Molloy DW, Smieja M, et al. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J Am Geriatr Soc. 2004 Mar;52(3):381-7.
Loi SM, Cations M, Velakoulis D. Young-onset dementia diagnosis, management and care: a narrative review. Med J Aust. 2023;218(4):182-189. doi:10.5694/mja2.51849. https://pubmed.ncbi.nlm.nih.gov/36807325/
Longpré F, et al. “Protection by EGb 761 against Beta-Amyloid-Induced Neurotoxicity: Involvement of NF-KappaB, SIRT1, and Mapks Pathways and Inhibition of Amyloid Fibril Formation.” Free Radic Biol Med. 41.12 (2006): 1781-94.
Lophatananon A, Mekli K, Cant R, et al. Shingles, Zostavax vaccination and risk of developing dementia: a nested case-control study-results from the UK Biobank cohort. BMJ Open. Oct 8 2021;11(10):e045871. doi:10.1136/bmjopen-2020-045871. https://bmjopen.bmj.com/content/bmjopen/11/10/e045871.full.pdf
Lu PH, Masterman DA, Mulnard R, et al. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol. 2006 Feb;63(2):177-85.
Lu Q, Lv H, Liu X, Zang L, Zhang Y, Meng Q. Lithium Therapy's Potential to Lower Dementia Risk and the Prevalence of Alzheimer's Disease: A Meta-Analysis. European neurology. 2024;87(2):93-104. doi:10.1159/000538846. https://www.ncbi.nlm.nih.gov/pubmed/38657568
Lu Y, Pike JR, Chen J, et al. Changes in Alzheimer Disease Blood Biomarkers and Associations With Incident All-Cause Dementia. Jama. 2024;332(15):1258-1269. doi:10.1001/jama.2024.6619. https://pubmed.ncbi.nlm.nih.gov/39068543/
Luan K, Rosales JL, Lee KY. “VIEWPOINT: Crosstalks Between Neurofibrillary Tangles and Amyloid Plaque Formation.” Ageing Res Rev. (2012) [Epub ahead of print]
Luchsinger JA, Cheng D, Tang MX, et al. Central obesity in the elderly is related to late-onset Alzheimer disease. Alzheimer Dis Assoc Disord. 2012 Apr;26(2): 101-5.
Lukiw WJ, et al. “A Role for Docosahexaenoic Acid-Derived Neuroprotectin D1 in Neural Cell Survival and Alzheimer Disease.” J Clin Invest. 115.10 (2005): 2774-83.
Luu-The V, Labrie F. “The Intracrine Sex Steroid Biosynthesis Pathways.” Prog Brain Res. 181. (2010): 177-92.
Lyketsos CG, Olin J. Depression in Alzheimer's disease: overview and treatment. Biological psychiatry. Aug 1 2002;52(3):243-252.
Ma QL, et al. “Beta-Amyloid Oligomers Induce Phosphorylation of Tau and Inactivation of Insulin Receptor Substrate via C-Jun N-Terminal Kinase Signaling: Suppression by Omega-3 Fatty Acids and Curcumin.” J Neurosci. 29.28 (2009): 9078-89.
MacMillan C. Lecanemab, the New Alzheimer's Treatment: 3 Things To Know. Yale Medicine. Updated 7/24/2023. Accessed 10/4/2024, https://www.yalemedicine.org/news/lecanemab-leqembi-new-alzheimers-drug
Magri F, Sarra S, Cinchetti W, et al. Qualitative and quantitative changes of melatonin levels in physiological and pathological aging and in centenarians. J Pineal Res. 2004 May;36(4):256-61.
Maki PM and Henderson VW. Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on. Climacteric. 2012 Jun;15(3):256-62.
Mallajosyula JK, Chinta SJ, Rajagopalan S, Nicholls DG, Andersen JK. Metabolic control analysis in a cellular model of elevated MAO-B: relevance to Parkinson's disease. Neurotoxicity research.Oct 2009;16(3):186-193.
Malyka AG et al. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010 Feb 12;70(3):287-312.
Manacuso M, et al. “Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders.” Curr Drug Targets. 11.1 (2010): 111-21.
Mandel S, et al. “Green Tea Catechins as Brain-Permeable, Natural Iron Chelators-Antioxidants for the Treatment of Neurodegenerative Disorders.” Mol Nutr Food Res. 50.2 (2006): 229-34.
Mandel SA, et al. “Understanding the Broad-Spectrum Neuroprotective Action Profile of Green Tea Polyphenols in Aging and Neurodegenerative Diseases.” J Alzheimers Dis. 25.2 (2011): 187-208.
Maqbool M, et al. Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease. Eur J Med Chem. 2016;107: 63-81.
Marchesi VT. “Alzheimer’s disease 2012: the great amyloid gamble.” Am J Pathol. 180.5 (2012): 1762-7.
Markova N, et al. Thiamine and benfotiamine improve cognition and ameliorate GSK-3β-associated stress-induced behaviours in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2017;75: 148-156.
Martin LJ. “Mitochondrial and Cell Death Mechanisms in Neurodegenerative Diseases.” Pharmaceuticals (Basel). 3.4 (2010): 839-915.
Mas E, et al. “Functional Vitamin E Deficiency in ApoE4 Patients with Alzheimer’s Disease.” Dement Geriatr Cogn Disord. 21.3 (2006): 198-204.
Mashayekh A, et al. “Effects of Ginkgo biloba on Cerebral Blood Flow Assessed by Quantitative MR Perfusion Imaging: A Pilot Study.” Neuroradiology. 53.3 (2011): 185-91.
Massoud F, Gauthier S. Update on the pharmacological treatment of Alzheimer's disease. Curr Neuropharmacol. 2010 Mar;8(1):69-80.
Matsunaga S, et al. Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis. J Alzheimers Dis. 2015;48(2): 403-410.
Mauer S, Vergne D, Ghaemi SN. Standard and trace-dose lithium: a systematic review of dementia prevention and other behavioral benefits. The Australian and New Zealand journal of psychiatry. Sep 2014;48(9):809-18. doi:10.1177/0004867414536932. https://www.ncbi.nlm.nih.gov/pubmed/24919696
Mayo Clinic. Alzheimer’s disease. Definition. Available at: http://www.mayoclinic.com/health/alzheimers-disease/DS00161/. Last updated January 18, 2011. Accessed August 2, 2012.
Mayo P, Pascual J, Crisman E, Dominguez C, Lopez MG, Leon R. Innovative pathological network-based multitarget approaches for Alzheimer's disease treatment. Medicinal research reviews. Apr 28 2024;doi:10.1002/med.22045. https://pubmed.ncbi.nlm.nih.gov/38678582/
Mayo W, et al. “Individual Differences in Cognitive Aging: Implication of Pregnenolone Sulfate.” Prog Neurobiol. 2003 Sep;71(1):43-8.
Mayo W, et al. “Pregnenolone Sulfate Enhances Neurogenesis and PSA-NCAM in Young and Aged Hippocampus.” Neurobiol Aging. 2005 Jan;26(1):103-14.
McCann SM, et al. “The Nitric Oxide Theory of Aging Revisited.” Ann N Y Acad Sci. 1057 (2005): 64-84.
McDonnell DP, Connor CE, Wijayaratne A, et al. “Definition of the Molecular and Cellular Mechanisms Underlying the Tissue-selective Agonist/Antagonist Activities of Selective Estrogen Receptor Modulators.” Endocrine Reviews. 57.1 (2002): 295-316.
McShane R, Westby MJ, Roberts E, et al. Memantine as a treatment for dementia. Cochrane. Updated 3/20/2019. Accessed 9/5/2024, https://www.cochrane.org/CD003154/DEMENTIA_memantine-treatment-dementia
Mehta M, Adem A, and Sabbagh M. New Acetylcholinesterase Inhibitors for Alzheimer's Disease. Int J Alzheimers Dis. 2012;2012:728983.
Meng Q, Ru J, Zhang G, et al. Re-evaluation of tacrine hepatotoxicity using gel entrapped hepatocytes. Toxicol Lett. 2007 Jan 30;168(2):140-7.
Merighi S, Nigro M, Travagli A, Gessi S. Microglia and Alzheimer's Disease. Int J Mol Sci. Oct 27 2022;23(21)doi:10.3390/ijms232112990. https://pubmed.ncbi.nlm.nih.gov/36361780/
Miklossy J. Alzheimer's disease - a neurospirochetosis. Analysis of the evidence following Koch's and Hill's criteria. J Neuroinflammation. 2011 Aug 4;8:90.
Milad SB, et al. “Inflammation and apoptosis in aortic tissues of aged type II diabetes: Amelioration with Mechanisms Underlying the Tissue-selective Agonist/Antagonist Activities of .” Life Sci. 86.23-24 (2010): 844-53.
Miller WL, “Androgen Biosynthesis from Cholesterol to DHEA.” Mol Cell Endocrinol. 198.1-2 (2002): 7-14.
Min JY, Min KB. Serum lycopene, lutein and zeaxanthin, and the risk of Alzheimer's disease mortality in older adults. Dement Geriatr Cogn Disord. 2014;37(3-4):246-256.
Mishra S, et al. “The Effect of Curcumin (Turmeric) on Alzheimer’s Disease: An Overview.” Ann Indian Acad Neurol. 11.1 (2008): 13-9.
Mizrahi EH, et al. “Plasma Total Homocysteine Levels, Dietary Vitamin B6 and Folate Intake in AD and Healthy Aging.” J Nutr Health Aging. 7.3 (2003): 160-5.
Moccetti T, Wullschleger C, Schmidt A, Aydogan C, Kreuter M. Bioactivity-based development of a wild green oat (Avena sativa L.) extract in support of mental health disorders. Zeitschrift für Phytotherapie.2006;27(S 1):P24.
Modrego PJ. Depression in Alzheimer's disease. Pathophysiology, diagnosis, and treatment. Journal of Alzheimer's disease : JAD. 2010;21(4):1077-1087.
Mold MJ, et al. Aluminum and Tau in Neurofibrillary Tangles in Familial Alzheimer’s Disease. Journal of Alzheimer's Disease Reports. 2021;5: 283-294.
Molloy DW, Standish TI, Zhou Q, Guyatt G. A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial. Int J Geriatr Psychiatry. 2013;28(5):463-470.
Montagnana M, et al. “Coffee Intake and Cardiovascular Disease: Virtue Does Not Take Center Stage.” Semin Thromb Hemos. 38.2 (2012): 164-77. Epub February 18, 2012.
Moreira PI, et al. “CoQ10 Therapy Attenuates Amyloid Beta-Peptide Toxicity in Brain Mitochondria Isolated from Aged Diabetic Rats.” Exp Neurol. 196.1 (2005): 112-9.
Moreira SC, Jansen AK, Silva FM. Dietary interventions and cognition of Alzheimer's disease patients: a systematic review of randomized controlled trial. Dementia & neuropsychologia. Jul-Sep 2020;14(3):258-282. doi:10.1590/1980-57642020dn14-030008. https://pubmed.ncbi.nlm.nih.gov/32973980/
Moreno M. “Cognitive improvement in mild to moderate Alzheimer’s dementia after treatment with the acetycholine precursor choline alfoscerate: A multicenter, double-blind, randomized, placebo-controlled trial.” Clin Ther. 25.1 (2003): 178-93.
Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytotherapy research : PTR. Mar 2009;23(3):367-372.
Morris MC, et al. “Dietary Niacin and the Risk of Incident Alzheimer’s Disease and of Cognitive Decline.” J Neurol Neurosurg Psychiatry. 75.8 (2004): 1093-9.
Motoko S, Motoko S, Kenichi Y, et al. Morphological and biochemical signs of age-related neurodegenerative changes in klotho mutant mice. Neuroscience. 2008;doi:10.1016/j.neuroscience.2008.01.032. https://pubmed.ncbi.nlm.nih.gov/18343589/
Mufson EJ, Counts SE, Perez SE, Ginsberg SD. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev Neurother. Nov 2008;8(11):1703-1718.
Mulder C, et al. “Low Vitamin B6 Levels Are Associated with White Matter Lesions in Alzheimer’s Disease.” J Am Geriatr Soc. 53.6 (2005): 1073-4.
Mullan K, Williams MA, Cardwell CR, et al. Serum concentrations of vitamin E and carotenoids are altered in Alzheimer's disease: A case-control study. Alzheimer's & dementia (New York, N Y). 2017;3(3):432-439.
Muller WE et al. Effects of piracetam on membrane fluidity in the aged mouse, rat, and human brain. Biochem Pharmacol. 1997 Jan 24;53(2):135-40.
Muñoz-Torrero D. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease. Curr Med Chem. 2008;15(24):2433-55.
Murase K, et al. “Stimulation of Nerve Growth Factor Synthesis/Secretion in Mouse Astroglial Cells by Coenzymes.” Biochem Mol Biol Int. 30.4 (1993): 615-21
Muronaga M, Terao T, Kohno K, Hirakawa H, Izumi T, Etoh M. Lithium in drinking water and Alzheimer's dementia: Epidemiological Findings from National Data Base of Japan. Bipolar disorders. Dec 2022;24(8):788-794. doi:10.1111/bdi.13257. https://www.ncbi.nlm.nih.gov/pubmed/36073313.
Nagahara AH, et al. “Neuroprotective Effects of Brain-Derived Neurotrophic Factor in Rodent and Primate Models of Alzheimer’s Disease.” Nat Med. 15.3 (2009): 331-7.
Nagatsu T, Sawada M. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells. Journal of neural transmission. Supplementum. 2006(71):53-65.
Nakagawa K, Kiko T, Miyazawa T, Carpentero Burdeos G, Kimura F, Satoh A, Miyazawa T. Antioxidant effect of astaxanthin on phospholipid peroxidation in human erythrocytes. The British journal of nutrition. Jun 2011;105(11):1563-1571.
Nakano M, Ubukata K, Yamamoto T, Yamaguchi H. Effect of pyrroloquinoline quinone (PQQ) on mental status of middle-aged and elderly persons. FOOD Style. 2009;21:13(7):50-3.
Nasrallah IM, Kuo PH, Nordberg A, Bohnen NI, Ponisio MR. The Impact of Amyloid and Tau PET on Alzheimer Disease Diagnostics: AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 2025;doi:10.2214/ajr.24.32325. https://pubmed.ncbi.nlm.nih.gov/40237426/
Nath A. Herpes Viruses, Alzheimer's Disease, and Related Dementias: Unifying or Confusing Hypothesis? Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. Jan 2019;16(1):180-181. doi:10.1007/s13311-018-00701-4.
Neal MA, Strawbridge R, Wing VC, Cousins DA, Thelwall PE. Human brain (7)Li-MRI following low-dose lithium dietary supplementation in healthy participants. J Affect Disord. Sep 1 2024;360:139-145. doi:10.1016/j.jad.2024.05.128. https://www.sciencedirect.com/science/article/pii/S0165032724008723?via%3Dihub
Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. Jun 6 2015;385(9984):2255-63. doi:10.1016/S0140-6736(15)60461-5. https://pubmed.ncbi.nlm.nih.gov/25771249/
NICE. National Institute for Health and Care Excellence. Dementia: Assessment, management and support for people living with dementia and their carers. Ch. 11 - Cholinesterase inhibitors and memantine for dementia. Updated 6/2018. Accessed 9/5/2024. https://pubmed.ncbi.nlm.nih.gov/30011160/
Nielsen RE, Grøntved S, Lolk A, Andersen K, Valentin JB. Real-world effects of anti-dementia treatment on mortality in patients with Alzheimer ́s dementia. Medicine (Baltimore). Nov 11 2022;101(45):e31625. doi:10.1097/md.0000000000031625. https://pubmed.ncbi.nlm.nih.gov/36397447/
Nieoullon A. [Acetylcholinesterase inhibitors in Alzheimer's disease: further comments on their mechanisms of action and therapeutic consequences]. Psychol Neuropsychiatr Vieil. 2010 Jun;8(2):123-31.
NLM. National Library of Medicine. DAILYMED. KINSUNLA - donanemab-azbt injection, solution. Updated 7/2/2024. Accessed 10/4/2024, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d1ff786-e577-410a-a273-c4d7d0e4e975
NLM. National Library of Medicine. DAILYMED. LEQEMBI - lecanemab injection, solution. Drug Label Information. Updated 7/22/2023. Accessed 10/4/2024, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d1ff786-e577-410a-a273-c4d7d0e4e975
Nolan JM, Loskutova E, Howard A, et al. The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial. J Alzheimers Dis. 2015;44(4):1157-1169.
Nolan JM, Mulcahy R, Power R, Moran R, Howard AN. Nutritional Intervention to Prevent Alzheimer's Disease: Potential Benefits of Xanthophyll Carotenoids and Omega-3 Fatty Acids Combined. J Alzheimers Dis. 2018;64(2):367-378.
Nolan JM, Power R, Howard AN, et al. Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease. J Alzheimers Dis. 2022;90(1):233-249. doi:10.3233/JAD-220556. https://pubmed.ncbi.nlm.nih.gov/36093704/
Nucci D, Sommariva A, Degoni LM, et al. Association between Mediterranean diet and dementia and Alzheimer disease: a systematic review with meta-analysis. Aging Clin Exp Res. Mar 22 2024;36(1):77. doi:10.1007/s40520-024-02718-6. https://pubmed.ncbi.nlm.nih.gov/38519775/
Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Current Alzheimer research. Jan 2013;10(1):104-7. https://www.eurekaselect.com/article/48585
Nunes PV, et al. “Lithium and Risk for Alzheimer’s Disease in Elderly Patients with Bipolar Disorder.” Br J Psychiatry. 190 (2007): 359-60.
O’Neill, et al. “Impact of the Selective Estrogen Receptor Modulator, Tamoxifen, on Neuronal Outgrowth and Survival following Toxic Insults Associated with Aging and Alzheimer’s disease.” Exp Neurol. 2004 Aug;188(2):268-78.
Ono K, et al. “Preformed Beta-Amyloid Fibrils Are Destabilized by Coenzyme Q10 in Vitro.” Biochem Biophys Res Commun. 330.1 (2005): 111-6.
Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. Jul 21 1990;336(8708):129-33. doi:10.1016/0140-6736(90)91656-u. https://pubmed.ncbi.nlm.nih.gov/1973470/
Ornish D, Madison C, Kivipelto M, et al. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: a randomized, controlled clinical trial. Alzheimers Res Ther. Jun 7 2024;16(1):122. doi:10.1186/s13195-024-01482-z. https://pubmed.ncbi.nlm.nih.gov/38849944/
Overk CR, Perez SE, Ma C, et al. Sex Steroid Levels and Ad-Like Pathology in 3xtgad Mice. [In Eng] J Neuroendocrinol. 2012 Aug 13;
Palmqvist S, Whitson HE, Allen LA, et al. Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings. Alzheimers Dement. 2025;21(7):e70535. doi:10.1002/alz.70535. https://pubmed.ncbi.nlm.nih.gov/40729527/
Palmqvist S, Zetterberg H, Mattsson N, et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology. 2015;85(14):1240-9. doi:10.1212/wnl.0000000000001991. https://pubmed.ncbi.nlm.nih.gov/26354982/
Pan L, Zhou Y, Li XF, Wan QJ, Yu LH. Preventive treatment of astaxanthin provides neuroprotection through suppression of reactive oxygen species and activation of antioxidant defense pathway after stroke in rats. Brain research bulletin. Apr 2017;130:211-220.
Pan X, et al. Long-Term Cognitive Improvement After Benfotiamine Administration in Patients with Alzheimer's Disease. Neurosci Bull. 2016;32(6): 591-596.
Pan Y, Wallace TC, Karosas T, Bennett DA, Agarwal P, Chung M. Association of Egg Intake With Alzheimer's Dementia Risk in Older Adults: The Rush Memory and Aging Project. J Nutr. Jul 2024;154(7):2236-2243. doi:10.1016/j.tjnut.2024.05.012. https://pubmed.ncbi.nlm.nih.gov/38782209/
Pangalos MN, et al. “Drug Development for CNS Disorders: Strategies for Balancing Risk and Reducing Attrition.” Nat Rev Drug Discov. 6 (2007): 521-32.
Park HA, Hayden MM, Bannerman S, Jansen J, Crowe-White KM. Anti-Apoptotic Effects of Carotenoids in Neurodegeneration. Molecules (Basel, Switzerland). 2020;25(15).
Parletta N, Milte CM, Meyer BJ. Nutritional modulation of cognitive function and mental health. The Journal of nutritional biochemistry. May 2013;24(5):725-743.
Pasinetti GM, Zhao Z, Qin W, et al. Caloric intake and Alzheimer's disease. Experimental approaches and therapeutic implications. Interdiscip Top Gerontol. 2007;35:159-75.
Pereira C, et al. “Neuroprotection Strategies: Effect of Vinpocetine in Vitro Oxidative Stress Models” [in Portuguese]. Acta Med Port. 16.6 (2003): 401-6.
Perry EK, et al. “Medicinal Plants and Alzheimer’s Disease: From Ethnobotany to Phytotherapy.” J Pharm Pharmacol. 51.5 (1999): 527-34.
Petersen RC, Wiste HJ, Weigand SD, et al. NIA-AA Alzheimer's Disease Framework: Clinical Characterization of Stages. Ann Neurol. 2021;89(6):1145-1156. doi:10.1002/ana.26071. https://pubmed.ncbi.nlm.nih.gov/33772866/
Pettegrew JW, et al. “Clinical and Neurochemical Effects of Acetyl-L-Carnitine in Alzheimer’s disease.” Neurobiol Aging. 16.1 (1995) 1-4.
Phan CW, Lee GS, Hong SL, Wong YT, Brkljaca R, Urban S, . . . Sabaratnam V. Hericium erinaceus (Bull.: Fr) Pers. cultivated under tropical conditions: isolation of hericenones and demonstration of NGF-mediated neurite outgrowth in PC12 cells via MEK/ERK and PI3K-Akt signaling pathways. Food Funct. Dec 2014;5(12):3160-3169.
Piura YD, Figdore DJ, Lachner C, et al. Diagnostic performance of plasma p-tau217 and Aβ42/40 biomarkers in the outpatient memory clinic. Alzheimer's & Dementia. 2025;21(6):e70316. doi:https://doi.org/10.1002/alz.70316. https://pubmed.ncbi.nlm.nih.gov/40476540/
Pocernich CB, et al. “In Vivo Glutathione Elevation Protects against Hydroxyl Free Radical-Induced Protein Oxidation in Rat Brain.” Neurochem Int. 36.3 (2000): 185-91.
Pocernich CB, et al. “Nutritional Approaches to Modulate Oxidative Stress in Alzheimer’s Disease.” Curr Alzheimer Res. 8.5 (2011): 452-69.
Poeckel D, Funk CD. The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease. Cardiovascular research. May 1 2010;86(2):243-253.
Pokrzyk J, Kulczyńska-Przybik A, Guzik-Makaruk E, Winkel I, Mroczko B. Clinical Importance of Amyloid Beta Implication in the Detection and Treatment of Alzheimer's Disease. Int J Mol Sci. 2025;26(5)doi:10.3390/ijms26051935. https://pubmed.ncbi.nlm.nih.gov/40076562/
Polleri A, et al. “Dementia: A Neuroendocrine Perspective.” J Endocrinol Invest. 25.1 (2002): 73-83.
Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med. 1995 Nov 9;333(19):1242-7.
Power R, Coen RF, Beatty S, et al. Supplemental Retinal Carotenoids Enhance Memory in Healthy Individuals with Low Levels of Macular Pigment in A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J Alzheimers Dis. 2018;61(3):947-961.
Press D, Alexander M. Cholinesterase inhibitors in the treatment of dementia. UpToDate. Updated 5/28/2024. Accessed 9/5/2024, https://www.uptodate.com/contents/cholinesterase-inhibitors-in-the-treatment-of-dementia
Press D, Buss SS. Treatment of Alzheimer disease. UpToDate. Updated 9/30/2021. Accessed 9/5/2024, https://www.uptodate.com/contents/treatment-of-alzheimer-disease
Prud'homme GJ, Kurt M, Wang Q. Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations. Front Aging. 2022;3:931331. doi:10.3389/fragi.2022.931331. https://pubmed.ncbi.nlm.nih.gov/35903083/
Qiu C, et al. “Vascular and Psychosocial Factors in Alzheimer’s Disease: Epidemiological Evidence toward Intervention.” J Alzheimers Dis. 20.3 (2010): 689-97.
Qiu C. Preventing Alzheimer's Disease by Targeting Vascular Risk Factors: Hope and Gap. J Alzheimers Dis. 2012 Jul 27. [Epub ahead of print]
Quadri P, et al. “Homocysteine and B Vitamins in Mild Cognitive Impairment and Dementia.” Clin Chem Lab Med. 43.10 (2005): 1096-100.
Quan W, Xu Y, Luo J, et al. Association of dietary meat consumption habits with neurodegenerative cognitive impairment: an updated systematic review and dose-response meta-analysis of 24 prospective cohort studies. Food Funct. Dec 13 2022;13(24):12590-12601. doi:10.1039/d2fo03168j. https://pubmed.ncbi.nlm.nih.gov/36385382/
Radanovic M, Singulani MP, De Paula VJR, Talib LL, Forlenza OV. An Overview of the Effects of Lithium on Alzheimer's Disease: A Historical Perspective. Pharmaceuticals (Basel). Apr 5 2025;18(4)doi:10.3390/ph18040532. https://www.ncbi.nlm.nih.gov/pubmed/40283967
Rafii MS, Walsh S, Little JT, et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 2011 Apr 19;76(16):1389-94.
Rahman SO, Panda BP, Parvez S, et al. Neuroprotective role of astaxanthin in hippocampal insulin resistance induced by Abeta peptides in animal model of Alzheimer's disease. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2019;110:47-58.
Ramirez A and Arbuckle MR. Synaptic Plasticity: The Role of Learning and Unlearning in Addiction and Beyond. Biol Psychiatry. 2016;80(9): e73-e75.
Ravaglia G, et al. “Homocysteine and Folate as Risk Factors for Dementia and Alzheimer Disease.” Am J Clin Nutr. 82.3 (2005): 636-43.
Remington R, Bechtel C, Larsen D, et al. A Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in Alzheimer's Disease. J Alzheimers Dis. 2015;45(2):395-405. doi:10.3233/JAD-142499. https://pubmed.ncbi.nlm.nih.gov/25589719/
Renzi LM, Dengler MJ, Puente A, Miller LS, Hammond BR, Jr. Relationships between macular pigment optical density and cognitive function in unimpaired and mildly cognitively impaired older adults. Neurobiol Aging. 2014;35(7):1695-1699.
Rex A, Spychalla M, Fink H. Treatment with reduced nicotinamide adenine dinucleotide (NADH) improves water maze performance in old Wistar rats. Behavioural brain research.Sep 23 2004;154(1):149-153.
Rezai-Zadeh K, et al. “Flavonoid-Mediated Presenilin-1 Phosphorylation Reduces Alzheimer’s Disease Beta-Amyloid Production.” J Cell Mol Med. 13.3 (2009): 574-88.
Rezai-Zadeh K, et al. “Green Tea Epigallocatechin-3-Gallate (EGCG) Modulates Amyloid Precursor Protein Cleavage and Reduces Cerebral Amyloidosis in Alzheimer Transgenic Mice.” J Neurosci. 25.38 (2005): 8807-14.
Rezai-Zadeh K, et al. “Green Tea Epigallocatechin-3-Gallate (EGCG) Reduces Beta-Amyloid Mediated Cognitive Impairment and Modulates Tau Pathology in Alzheimer Transgenic Mice.” Brain Res. 12.1214 (2008): 177-87.
Richard T, et al. “Neuroprotective Properties of Resveratrol and Derivatives.” Ann N Y Acad Sci. 1215 (2011): 103-8.
Richter Y, et al. “The Effect of Phosphatidylserine-containing Omega-3 Fatty Acids on Memory Abilities in Subjects with Subjective Memory Complaints: A Pilot Study.” Clin Interv Aging. 5 (2010): 313-6.
Ringman JM, et al. “A Potential Role of the Curry Spice Curcumin in Alzheimer’s Disease.” Curr Alzheimer Res. 2.2 (2005): 131-6.
Rosales-Corral SA, et al. “Alzheimer’s Disease: Pathological Mechanisms and the Beneficial Role of Melatonin.” J Pineal Res. 52.2 (2012): 167-202.
Rosenberg A, Ngandu T, Rusanen M, et al. Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: The FINGER trial. Alzheimers Dement. Mar 2018;14(3):263-270. doi:10.1016/j.jalz.2017.09.006. https://pubmed.ncbi.nlm.nih.gov/29055814/
Rusanen M, Solomon A, et al. Effect of a multi-domain lifestyle intervention on cardiovascular risk in older people: the FINGER trial. Eur Heart J. Jun 1 2022;43(21):2054-2061. doi:10.1093/eurheartj/ehab922. https://pubmed.ncbi.nlm.nih.gov/35051281/
Sadowsky CH, Galvin JE. “Guidelines for management of cognitive and behavioral problems in dementia.” J Am Board Fam Med. 25.3 (2012): 350-66.
Saito ER, et al. Alzheimer's disease alters oligodendrocytic glycolytic and ketolytic gene expression. Alzheimer's & Dementia. 2021 Mar 2 [Online ahead of print]. https://pubmed.ncbi.nlm.nih.gov/33650792/
Salminen A, et al. “Inflammation in Alzheimer’s disease: Amyloid-β Oligomers Trigger Innate Immunity Defence via Pattern Recognition Receptors.” Prog Neurobiol. 87.3 (2009):181-194.
Sanchez PE, Zhu L, Verret L, et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A. 2012 Aug 6. [Epub ahead of print]
Sasaki Y, Araki T, Milbrandt J. Stimulation of nicotinamide adenine dinucleotide biosynthetic pathways delays axonal degeneration after axotomy. The Journal of neuroscience: the official journal of the Society for Neuroscience.Aug 16 2006;26(33):8484-8491.
Sastre M, Gentleman SM. NSAIDs: How they Work and their Prospects as Therapeutics in Alzheimer's Disease. Front Aging Neurosci. 2010 May 18;2:20.
Satoh A, Tsuji S, Okada Y, Murakami N, Urami M, Nakagawa K, . . . Shirasawa T. Preliminary Clinical Evaluation of Toxicity and Efficacy of A New Astaxanthin-rich Haematococcus pluvialis Extract. Journal of clinical biochemistry and nutrition. May 2009;44(3):280-284.
Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G, Löffler J, Richards JG. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience.Sep 1994;62(1):15-30.
Scherrer J, Salas J, Jacobs C, Wiemken T. Lower dementia risk in patients vaccinated against herpes zoster. Ann Fam Med. Apr 1 2022;(20 Suppl 1)https://pubmed.ncbi.nlm.nih.gov/36696249/
Schmitz C, et al. “Hippocampal Neuron Loss Exceeds Amyloid Plaque Load in a Transgenic Mouse Model of Alzheimer’s Disease.” Am J Pathol. 2004 Apr;164(4):1495-502.
Schneider LS, et al. “A Randomized, Double-Blind, Placebo-Controlled Trial of Two Doses of Ginkgo biloba Extract in Dementia of the Alzheimer’s Type.” Curr Alzheimer Res. 2.5 (2005): 541-51.
Schreiber S, et al. “An Open Trial of Plant-Source Derived Phosphatydilserine for Treatment of Age-Related Cognitive Decline.” Isr J Psychiatry Relat Sci. 37.4 (2000): 302-7.
Schulte-Herbrüggen O, Jockers-Scherübl MC, Hellweg R. Neurotrophins: from pathophysiology to treatment in Alzheimer's disease. Curr Alzheimer Res. 2008 Feb;5(1):38-44.
Schumacher M, et al. “Local Synthesis and Dual Actions of Progesterone in the Nervous System: Neuroprotection and Myclination.” Growth Horm IGF Res. 14.A (2004):S18-33.
Schuster D, Rajendran A, Hui SW, Nicotera T, Srikrishnan T, Kruzel ML. Protective effect of colostrinin on neuroblastoma cell survival is due to reduced aggregation of beta-amyloid. Neuropeptides.Aug 2005;39(4):419-426.
Sehgal N, Gupta A, Valli RK,et al. Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci U S A. 2012 Feb 28;109(9):3510-5. Epub 2012 Jan 30.
Senin U, Parnetti L, Barbagallo-Sangiorgi G, et al. Idebenone in Senile Dementia of Alzheimer Type: A Multicentre Study. [In eng] Arch Gerontol Geriatr. 1992 Nov-Dec; 15(3): 249-60.
Semba RD, Moghekar AR, Hu J, et al. Klotho in the cerebrospinal fluid of adults with and without Alzheimer's disease. Neurosci Lett. Jan 13 2014;558:37-40. doi:10.1016/j.neulet.2013.10.058. https://pubmed.ncbi.nlm.nih.gov/24211693/
Serot JM, et al. “CSF-Folate Levels Are Decreased in Late-Onset AD Patients.” J Neural Transm. 108.1 (2001): 93-9.
Servick K. Alzheimer's drug approved despite doubts about effectiveness: FDA breaks from advisers to clear Aduhelm based on reduction of toxic brain plaques. Updated 6/7/2021. Accessed 9/5/2024, https://www.science.org/content/article/alzheimer-s-drug-approved-despite-doubts-about-effectiveness
Shah NS, Vidal JS, Masaki K. Midlife blood pressure, plasma β-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study. Hypertension. 2012 Apr;59(4):780-6. Epub 2012 Mar 5.
Shi J, et al. “Polyphenolics in Grape Seeds: Biochemistry and Functionality.” J Med Food. 6.4 (2003): 291-9.
Shireen KF, et al. “Effects of Dietary Vitamin E, C and Soybean Oil Supplementation on Antioxidant Enzyme Activities in Liver and Muscles of Rats.” Food Chem Toxicol. 46.10 (2008): 3290-3294.
Shyh-Hwa L, et al. “Docosahexaenoic Acid and Phosphatidylserine Supplementations Improve Antioxidant Activities and Cognitive Functions of the Developing Brain on Pentylenetetrazol-Induced Seizure Model.” Brain Res. 1451. (2012): 19-26.
Siervo M, Shannon OM, Llewellyn DJ, Stephan BC, Fontana L. Mediterranean diet and cognitive function: From methodology to mechanisms of action. Free Radic Biol Med. Nov 20 2021;176:105-117. doi:10.1016/j.freeradbiomed.2021.09.018. https://pubmed.ncbi.nlm.nih.gov/34562607/
Sifi N, Martin-Eauclaire MF, Laraba-Djebari F. K(+) channel blocker-induced neuroinflammatory response and neurological disorders: immunomodulatory effects of astaxanthin. Inflammation research : official journal of the European Histamine Research Society ... [et al.]. Aug 2016;65(8):623-634.
Silva BC, de Miranda AS, Rodrigues FG, Silveira AL, Resende GH, Moraes MF, . . . Rachid MA. The 5-lipoxygenase (5-LOX) Inhibitor Zileuton Reduces Inflammation and Infarct Size with Improvement in Neurological Outcome Following Cerebral Ischemia. Current neurovascular research. 2015;12(4):398-403.
Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512-527. doi:10.1001/jama.2023.13239. https://pubmed.ncbi.nlm.nih.gov/37459141/
Singhaarachchi PH, Antal P, Calon F, et al. Aging, sex, metabolic and life experience factors: Contributions to neuro-inflammaging in Alzheimer's disease research. Neuroscience and biobehavioral reviews. Jul 2024;162:105724. doi:10.1016/j.neubiorev.2024.105724. https://pubmed.ncbi.nlm.nih.gov/38762130/
Singhrang N, Tocharus C, Thummayot S, Sutheerawattananonda M, Tocharus J. Protective effects of silk lutein extract from Bombyx mori cocoons on beta-Amyloid peptide-inducedapoptosis in PC12 cells. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2018;103:582-587.
Singulani MP, Ferreira AFF, Figueroa PS, et al. Lithium and disease modification: A systematic review and meta-analysis in Alzheimer's and Parkinson's disease. Ageing Res Rev. Mar 2024;95:102231. doi:10.1016/j.arr.2024.102231. https://www.ncbi.nlm.nih.gov/pubmed/38364914
Sitges M, et al. “Vinpocetine Blockade of Sodium Channels Inhibits the Rise in Sodium and Calcium Induced by 4-Aminopyridine in Synaptosomes.” Neurochem Int. 46.7 (2005): 533-40.
Slutsky I, et al. “Enhancement of Learning and Memory by Elevating Brain Magnesium.” Neuron. 65.2 (2010): 165-77.
Soininen H, Solomon A, Visser PJ, et al. 24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurol. Dec 2017;16(12):965-975. doi:10.1016/S1474-4422(17)30332-0. https://pubmed.ncbi.nlm.nih.gov/29097166/
Soininen H, Solomon A, Visser PJ, et al. 36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease. Alzheimers Dement. Jan 2021;17(1):29-40. doi:10.1002/alz.12172. https://pubmed.ncbi.nlm.nih.gov/32920957/
Solch RJ, Aigbogun JO, Voyiadjis AG, et al. Mediterranean diet adherence, gut microbiota, and Alzheimer's or Parkinson's disease risk: A systematic review. J Neurol Sci. Mar 15 2022;434:120166. doi:10.1016/j.jns.2022.120166. https://pubmed.ncbi.nlm.nih.gov/35144237/
Solomon A, Turunen H, Ngandu T, et al. Effect of the Apolipoprotein E Genotype on Cognitive Change During a Multidomain Lifestyle Intervention: A Subgroup Analysis of a Randomized Clinical Trial. JAMA Neurol. Apr 1 2018;75(4):462-470. doi:10.1001/jamaneurol.2017.4365. https://pubmed.ncbi.nlm.nih.gov/29356827/
Soscia SJ, Kirby JE, Washicosky KJ, et al. The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One. 2010 Mar 3;5(3):e9505.
Sostres C, Gargallo CJ, Arroyo MT, et al. “Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract.” Best Prac Res Clin Gastroenterol. 24.2 (2010):121-32.
Srinivasan V, et al. “Melatonin in Alzheimer’s Disease and Other Neurodegenerative Disorders.” Behav Brain Funct. 4.2 (2006): 15.
Srivastava S. Emerging therapeutic roles for NAD(+) metabolism in mitochondrial and age-related disorders. Clinical and translational medicine.Dec 2016;5(1):25.
St. George-Hyslop PH, et al. “Will Anti-Amyloid Therapies Work for Alzheimer’s Disease?” Lancet. 2008 Jul 19;372(9634):180-2.
Stern: Massachusetts General Hospital Comprehensive Clinical Psychiatry, 1st ed. Copyright © 2008 Mosby, An Imprint of Elsevier. Available at http://www.mdconsult.com/books/page.do?eid=4-u1.0-B978-0-323-04743-2..50021-4--cesec5&isbn=978-0-323-04743-2&uniqId=348489237-3#4-u1.0-B978-0-323-04743-2..50021-4--cesec5 Accessed 7/31/2012.
Stewart MG. Colostrinin: a naturally occurring compound derived from mammalian colostrum with efficacy in treatment of neurodegenerative diseases, including Alzheimer's. Expert opinion on pharmacotherapy.Oct 2008;9(14):2553-2559.
Suchy J, et al. “Dietary supplementation with a combination of α-lipoic acid, acetyl-l-carnitine, glycerophosphocoline, docosahexaenoic acid, and phosphatidylserine reduces oxidative damage to murine brain and improves cognitive performance.” Nut Res. 29.1 (2009): 70-74.
Sun QQ, et al. “Huperzine-A Capsules Enhance Memory and Learning Performance in 34 Pairs of Matched Adolescent Students.” Zhongguo Yao Li Xue Bao. 20.7 (1999): 601-3.
Sun XJ, et al. Benfotiamine prevents increased β-amyloid production in HEK cells induced by high glucose. Neurosci Bull. 2012;28(5): 561-566.
Swanson D, et al. “Omega-3 fatty acids DHA and EPA: Health Benefits throughout Life.” Adv Nutr. 3.1 (2012): 1-7
Szilagyi G, et al. “Effects of Vinpocetine on the Redistribution of Cerebral Blood Flow and Glucose Metabolism in Chronic Ischemic Stroke Patients: A PET Study.” J Neurol Sci. Mar 15 (2005); 229-230: 275-84.
Taksima T, Chonpathompikunlert P, Sroyraya M, Hutamekalin P, Limpawattana M, Klaypradit W. Effects of Astaxanthin from Shrimp Shell on Oxidative Stress and Behavior in Animal Model of Alzheimer's Disease. Mar Drugs. 2019;17(11).
Talebi S, Asoudeh F, Naeini F, Sadeghi E, Travica N, Mohammadi H. Association between animal protein sources and risk of neurodegenerative diseases: a systematic review and dose-response meta-analysis. Nutr Rev. Aug 10 2023;81(9):1131-1143. doi:10.1093/nutrit/nuac114. https://pubmed.ncbi.nlm.nih.gov/36647769/
Tao R, et al. “Pyrroloquinoline quinone preserves mitochondrial function and prevents oxidative injury in Alzheimer’s diseaseult rat cardiac myocytes.” Biochem Biophys Res Commune. 363.2 (2007):257-262. Epub ahead of printTarawneh R and Holtzman DM. The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harb Perspect Med. 2012;2(5):a006148.
Tarawneh R, Holtzman DM. “The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment.” Cold Spring Harb Perspect Med. 2.5 (2012):a006148.
Taquet M, Dercon Q, Todd JA, Harrison PJ. The recombinant shingles vaccine is associated with lower risk of dementia. Nat Med. 2024; 30(10): 2777-2781. doi:10.1038/s41591-024-03201-5. https://pubmed.ncbi.nlm.nih.gov/39053634/
Tchantchou F, et al. “N-Acetyl Cysteine Alleviates Oxidative Damage to Central Nervous System of Apoe-Deficient Mice Following Folate and Vitamin E-Deficiency.” J Alzheimers Dis. 7.2 (2005): 135-8.
Teng CC, Yang YT, Chen YC, et al. “Role of WWOX/WOX1 in Alzheimer’s disease pathology and in cell death signaling.” Front Biosci (Elite Ed). 4 (2012): 1951-65.
Theendakara V, et al. Transcriptional Effects of ApoE4: Relevance to Alzheimer's Disease. Mol Neurobiol. 2018;55(6): 5243-5254.
Tobinick EL and Gross H. “Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration.” J Neuroinflammation. 5 (2008b): 2.
Tobinick EL and Gross H. “Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease.” BMC Neurol. 8 (2008a): 27.
Tobinick EL. “Deciphering the Physiology Underlying the Rapid Clinical Effects of Perispinal Etanercept in Alzheimer’s disease.” Curr Alzheimer Res. 9.1 (2012): 99-109.
Tomljenovic L. Aluminum and Alzheimer's disease: after a century of controversy, is there a plausible link? J Alzheimers Dis. 2011;23(4): 567-598.
Trenkwalder P. “The Study on Cognition and Prognosis in the Elderly (SCOPE)—Recent Analyses.” J Hypertens Suppl. 24.1 (2006): S107-14.
Truebinding Inc. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT05074498. Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants with Alzheimer's Disease. Updated 11/18/2023. Accessed 10/8/2024, https://clinicaltrials.gov/study/NCT05074498
TrueBinding. Expanded Access Program (EAP) for TB006. Accessed 9/13/2024a, https://www.truebinding.com/expanded-access
TrueBinding. TB006, a humanized monoclonal antibody targeting Galectin-3, is a potentially revolutionary drug for Alzheimer's Disease treatment. Accessed 10/8/2024b, https://www.truebinding.com/ourscience
Truong C, Recto C, Lafont C, Canoui-Poitrine F, Belmin JB, Lafuente-Lafuente C. Effect of Cholinesterase Inhibitors on Mortality in Patients With Dementia: A Systematic Review of Randomized and Nonrandomized Trials. Neurology. Nov 14 2022;99(20):e2313-e2325. doi:10.1212/wnl.0000000000201161. https://pubmed.ncbi.nlm.nih.gov/36096687/
Tsai GE, k WE, Gunther J, et al. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. Am J Psychiatry. 1999 Mar;156(3):467-9.
Tsai JH, Huang CF, Lin MN, Chang CE, Chang CC, Lin CL. Taiwanese Vegetarians Are Associated with Lower Dementia Risk: A Prospective Cohort Study. Nutrients. Jan 28 2022;14(3)doi:10.3390/nu14030588. https://pubmed.ncbi.nlm.nih.gov/35276947/
Tsai KJ, et al. “G-CSF Rescues the Memory Impairment of Animal Models of Alzheimer’s Disease.” J Exp Med. 204.6 (2007): 1273-80.
Tsai-Teng T, Chin-Chu C, Li-Ya L, Wan-Ping C, Chung-Kuang L, Chien-Chang S, . . . Shiao YJ. Erinacine A-enriched Hericium erinaceus mycelium ameliorates Alzheimer's disease-related pathologies in APPswe/PS1dE9 transgenic mice. J Biomed Sci. Jun 27 2016;23(1):49.
Tu XK, Zhang HB, Shi SS, Liang RS, Wang CH, Chen CM, Yang WZ. 5-LOX Inhibitor Zileuton Reduces Inflammatory Reaction and Ischemic Brain Damage Through the Activation of PI3K/Akt Signaling Pathway. Neurochemical research. Oct 2016;41(10):2779-2787.
Tucker KL, et al. “High Homocysteine and Low B Vitamins Predict Cognitive Decline in Aging Men: The Veterans Affairs Normative Aging Study.” Am J Clin Nutr. 82.3 (2005): 627-35.
Twarowski B, Herbet M. Inflammatory Processes in Alzheimer's Disease-Pathomechanism, Diagnosis and Treatment: A Review. Int J Mol Sci. Mar 30 2023;24(7)doi:10.3390/ijms24076518. https://pubmed.ncbi.nlm.nih.gov/37047492/
Tzeng TT, Chen CC, Chen CC, Tsay HJ, Lee LY, Chen WP, . . . Shiao YJ. The Cyanthin Diterpenoid and Sesterterpene Constituents of Hericium erinaceus Mycelium Ameliorate Alzheimer's Disease-Related Pathologies in APP/PS1 Transgenic Mice. International journal of molecular sciences. Feb 17 2018;19(2).
Ukraintseva S, Yashkin A, Duan M, et al. Repurposing of existing vaccines for personalized prevention of Alzheimer’s disease: Vaccination against pneumonia may reduce AD risk depending on genotype: Genetics/genetic factors of Alzheimer's disease. Alzheimer's & Dementia. 12/01 2020;16doi:10.1002/alz.046751. https://alz-journals.onlinelibrary.wiley.com/doi/abs/10.1002/alz.046751
Upadhyaya P, Seth V, Ahmad M. “Therapy for Alzheimer’s disease: An update.” African Journal of Pharmacy and Pharmacology. 4.6 (2010): 408-21.
Vagnozzi AN, Giannopoulos PF, Pratico D. The direct role of 5-lipoxygenase on tau pathology, synaptic integrity and cognition in a mouse model of tauopathy. Translational psychiatry. Dec 18 2017;7(12):1288.
Van der Auwera I, Wera S, Van Leuven F, et al. “A ketogenic diet reduces amyloid beta 40 and 42 in mouse model of Alzheimer’s disease.” Nutr Metab (Lond). 2 (2005):28.
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. Jan 5 2023;388(1):9-21. doi:10.1056/NEJMoa2212948. https://pubmed.ncbi.nlm.nih.gov/36449413/
van Himbergen TM, et al. “Biomarkers for Insulin Resistance and Inflammation and the Risk for All-Cause Dementia and Alzheimer Disease: Results From the Framingham Heart Study.” Arch Neurol. (2012): Epub ahead of print January 2, 2012. doi:10.1001/archneurol.2011.670.
van Praag H. “Exercise and the Brain: Something to Chew On.” Trends Neurosci. 32.5 (2009): 283-90.
Ven Murthy MR, et al. “Scientific Basis for the Use of Indian Ayurvedic Medicinal Plants in the Treatment of Neurodegenerative Disorders: Ashwagandha.” Cent Nerv Syst Agents Med Chem. 10.3 (2010): 238-46.
Vest RS, and Pike CJ. Gender, sex steroid hormones, and Alzheimer's disease. Horm Behav. 2012 Apr 19. [Epub ahead of print]
Villoz F, Filippini T, Ortega N, et al. Dairy Intake and Risk of Cognitive Decline and Dementia: A Systematic Review and Dose-Response Meta-Analysis of Prospective Studies. Adv Nutr. Jan 2024;15(1):100160. doi:10.1016/j.advnut.2023.100160. https://pubmed.ncbi.nlm.nih.gov/38043604/
Vingtdeux V, Dreses-Werringloer U, Zhao H, et al. “Therapeutic potential of resveratrol in Alzheimer’s disease.” BMC Neurosci. 9(Suppl 2) (2008): S6.
Virmani MA, et al. “The Action of Acetyl-L-Carnitine on the Neurotoxicity Evoked by Amyloid Fragments and Peroxide on Primary Rat Cortical Neurones.” Ann N Y Acad Sci. 939 (2001): 162-78.
Waegemans T et al. Clinical efficacy of piracetam in cognitive impairment: a meta-analysis. Dement Geriatr Cogn Disord. 2002;13(4):217-24.
Walker D, et al. “Anti-Inflammatory and Immune Therapy for Alzheimer’s Disease: Current Status and Future Directions.” Curr Neuropharmacol. 5.4 (2007): 232-43.
Walter A, et al. “ Glycerophosphocholine is Elevated in Cerebrospinal Fluid of Alzheimer Patients.” Neurobiol Aging. 25.10 (2004): 1299-303.
Wang BS, et al. “Efficacy and Safety of Natural Acetylcholinesterase Inhibitor Huperzine A in the Treatment of Alzheimer’s Disease: An Updated Meta-Analysis.” J Neural Transm. 116.4 (2009): 457-65.
Wang HX, et al. “Vitamin B(12) and Folate in Relation to the Development of Alzheimer’s Disease.” Neurology. 56.9 (2001): 1188-94.
Wang J, et al. “Grape-Derived Polyphenolics Prevent Alpha Beta Oligomerization and Attenuate Cognitive Deterioration in a Mouse Model of Alzheimer’s Disease.” J Neurosci. 28.25 (2008): 6388-92.
Wang JZ, et al. “Role of Melatonin in Alzheimer-Like Neurodegeneration.” Acta Pharmacol Sin. 27.1 (2006a): 41-9.
Wang R, et al. “Progress in Studies of Huperzine A: A Natural Cholinesterase Inhibitor from Chinese Herbal Medicine.” Acta Pharmacol Sin. 27.1 (2006b): 1-26.
Wang X, Su B, Perry G, et al. Insights into amyloid-beta-induced mitochondrial dysfunction in Alzheimer disease. Free Radic Bio Med. 43.12 (2007): 1569-73.
Wang X, Xin Z, Li X, et al. Mediterranean diet and dementia: MRI marker evidence from meta-analysis. Eur J Med Res. Jan 16 2025;30(1):32. doi:10.1186/s40001-025-02276-1. https://pubmed.ncbi.nlm.nih.gov/39815306/
Wang XD, Zhang JM, Yang HH, et al. Modulation of NMDA receptor by huperzine A in rat cerebral cortex. Zhongguo Yao Li Xue Bao. 1999 Jan;20(1):31-5.
Warren-Gash C, Forbes HJ, Williamson E, et al. Human herpesvirus infections and dementia or mild cognitive impairment: a systematic review and meta-analysis. Sci Rep. Mar 18 2019;9(1):4743. doi:10.1038/s41598-019-41218-w. https://www.nature.com/articles/s41598-019-41218-w.pdf
Watkins PB, Dube LM, Walton-Bowen K, Cameron CM, Kasten LE. Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. Drug safety. 2007;30(9):805-815.
Weill-Engerer S, et al. “Neurosteroid Quantification in Human Brain Regions: Comparison between Alzheimer’s and Nondemented Patients.” J Clin Endocrinol Metab. 87.11 (2002): 5138-43.
William BW, Cruz C. “Impact of NSAIDs on Cardiovascular Risk and Hypertension.” Ital J Med. 5.3 (2011):175-183.
Winter B et al. High impact running improves learning. Neurobiol Learn Mem. 2007 May;87(4):597-609.
Withington CG, Turner RS. Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease. Front Neurol. 2022;13:862369. doi:10.3389/fneur.2022.862369. https://pubmed.ncbi.nlm.nih.gov/35401412/
Wolk DAD, B. D.; DeKosky, S. T.; Wilterdink, J. L. Clinical Features and DIagnosis of Alzheimer Disease. UpToDate. Last updated 05/2025. Accessed 9/3/2025.
Won E. and Kim Y-K. An Oldie but Goodie: Lithium in the Treatment of Bipolar Disorder through Neuroprotective and Neurotrophic Mechanisms. International journal of molecular sciences. 2017;18(12): 2679.
Wong KH, Kanagasabapathy G, Naidu M, David P, Sabaratnam V. Hericium erinaceus (Bull.: Fr.) Pers., a medicinal mushroom, activates peripheral nerve regeneration. Chin J Integr Med. Oct 2016;22(10):759-767.
Wong RH, Howe PR, Bryan J, Coates AM, Buckley JD, Berry NM. Chronic effects of a wild green oat extract supplementation on cognitive performance in older adults: a randomised, double-blind, placebo-controlled, crossover trial. Nutrients.May 2012;4(5):331-342.
World Health Organization: Dementia. Last updated 03/31/2025. Accessed 08/28/2025. https://www.who.int/news-room/fact-sheets/detail/dementia
Wu A, et al. “Dietary Omega-3 Fatty Acids Normalize BDNF Levels, Reduce Oxidative Damage, and Counteract Learning Disability after Traumatic Brain Injury in Rats.” J Neurotrauma. 21.10 (2004a): 1457-67.
Wu H, Niu H, Shao A, Wu C, Dixon BJ, Zhang J, . . . Wang Y. Astaxanthin as a Potential Neuroprotective Agent for Neurological Diseases. Marine drugs. Sep 11 2015;13(9):5750-5766.
Wu Q, Zhang XS, Wang HD, Zhang X, Yu Q, Li W, . . . Wang XL. Astaxanthin activates nuclear factor erythroid-related factor 2 and the antioxidant responsive element (Nrf2-ARE) pathway in the brain after subarachnoid hemorrhage in rats and attenuates early brain injury. Marine drugs. Dec 18 2014;12(12):6125-6141.
Wu X, et al. “Lipophilic and Hydrophilic Antioxidant Capacities of Common Foods in the United States.” J Agric Food Chem. 52.12 (2004b): 4026-37.
Xiong MH, et al. APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Sci Transl Med. 2021;13(581).
Xiong X, Hu T, Yin Z, et al. Research advances in the study of sleep disorders, circadian rhythm disturbances and Alzheimer's disease. Front Aging Neurosci. 2022;14:944283. https://pubmed.ncbi.nlm.nih.gov/36062143/
Xu WL, et al. Fratiglioni. Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study. Diabetologia. 2009;52(6): 1031-1039.
Yaffe K, et al. “Effect of Raloxifene on Prevention of Dementia and Cognitive Impairment in Older Women: The Multiple Outcomes of Raloxifene (MORE) Randomized Trial.” Am J Psychiatry. 2005 Apr;162(4):683-90.
Yamaguchi K, et al. “Stimulation of Nerve Growth Factor Production by Pyrroloquinoline Quinone and Its Derivatives in Vitro and in Vivo.” Biosci Biotechnol Biochem. 57.7 (1993): 1231-3.
Yaffe K, Vittinghoff E, Dublin S, et al. Effect of Personalized Risk-Reduction Strategies on Cognition and Dementia Risk Profile Among Older Adults: The SMARRT Randomized Clinical Trial. JAMA Intern Med. Jan 1 2024;184(1):54-62. doi:10.1001/jamainternmed.2023.6279. https://pubmed.ncbi.nlm.nih.gov/38010725/
Yang F, et al. “Curcumin Inhibits Formation of Amyloid Beta Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo.” J Biol Chem. 280.7 (2005): 5892-901.
Yang X, Wei HM, Hu GY, et al. Combining antioxidant astaxantin and cholinesterase inhibitor huperzine A boosts neuroprotection. Molecular medicine reports. 2020;21(3):1043-1050.
Yang X, et al. “Coenzyme Q10 Attenuates Beta-Amyloid Pathology in the Aged Transgenic Mice with Alzheimer Presenilin 1 Mutation.” J Mol Neurosci. 34.2 (2008): 165-71.
Yao ZX, et al. “Ginkgo biloba Extract (Egb 761) Inhibits Beta-Amyloid Production by Lowering Free Cholesterol Levels.” J Nutr Biochem. 15.12 (2004): 749-56.
Yarns BC, Holiday KA, Carlson DM, Cosgrove CK, Melrose RJ. Pathophysiology of Alzheimer's Disease. The Psychiatric clinics of North America. Dec 2022;45(4):663-676. doi:10.1016/j.psc.2022.07.003. https://pubmed.ncbi.nlm.nih.gov/36396271/
Yeh TS, Curhan GC, Yawn BP, Willett WC, Curhan SG. Herpes zoster and long-term risk of subjective cognitive decline. Alzheimers Res Ther. Aug 14 2024;16(1):180. doi:10.1186/s13195-024-01511-x. https://pubmed.ncbi.nlm.nih.gov/39138535/
Yilmaz N. “Relationship between paraoxonase and homocysteine: crossroads of oxidative diseases.” Arch Med Sci. 8.1: 138-53.
Young G, et al. “Omega-3 Fatty Acids and Neuropsychiatric Disorders.” Reprod Nutr Dev 45.1 (2005): 1-28.
Yulug B, Altay O, Li X, et al. Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial. Translational neurodegeneration. Jan 26 2023;12(1):4. doi:10.1186/s40035-023-00336-2. https://pubmed.ncbi.nlm.nih.gov/36703196/
Yurko-Mauro K, et al. “Beneficial Effects of Docosahexaenoic Acid on Cognition in Age-Related Cognitive Decline.” Alzheimers Dement. 6.6 (2010): 456-64.
Zablocka A, Janusz M. Effect of the proline-rich polypeptide complex/colostrinin on the enzymatic antioxidant system. Arch Immunol Ther Exp (Warsz).Oct 2012;60(5):383-390.
Zablocka A, Ogorzalek A, Macala J, Janusz M. A proline-rich polypeptide complex (PRP) influences inducible nitric oxide synthase in mice at the protein level. Nitric oxide: biology and chemistry. Aug 01 2010;23(1):20-25.
Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the CacheCounty Study. JAMA. 2002 Nov 6;288(17):2123-9.
Zapp LM, Slaga TJ, Zhao J. et al. Method for enhancing post-processing content of beneficial compounds in beverages naturally - United States Patent Application 20100183790. Publication Date: 2010-07-22. Available at: http://patent.ipexl.com/U2S/20100183790.html accessed 7/25/2012.
Zeng C-Y, Yang T-T, Zhou H-J, et al. Lentiviral vector–mediated overexpression of Klotho in the brain improves Alzheimer's disease–like pathology and cognitive deficits in mice. Neurobiology of Aging. 2019;78:18-28. doi:https://doi.org/10.1016/j.neurobiolaging.2019.02.003. https://pubmed.ncbi.nlm.nih.gov/30851437/
Zeng X, Ling H, Yang J, Chen J, Guo S. Proteome analysis provides insight into the regulation of bioactive metabolites in Hericium erinaceus. Gene. Aug 5 2018;666:108-115.
Zhang CC, Cao CY, Kubo M, Harada K, Yan XT, Fukuyama Y, Gao JM. Chemical Constituents from Hericium erinaceus Promote Neuronal Survival and Potentiate Neurite Outgrowth via the TrkA/Erk1/2 Pathway. International journal of molecular sciences. Jul 30 2017;18(8).
Zhang H, Greenwood DC, Risch HA, Bunce D, Hardie LJ, Cade JE. Meat consumption and risk of incident dementia: cohort study of 493,888 UK Biobank participants. Am J Clin Nutr. Jul 1 2021;114(1):175-184. doi:10.1093/ajcn/nqab028. https://pubmed.ncbi.nlm.nih.gov/33748832/
Zhang J, An S, Hu W, Teng M, Wang X, Qu Y, . . . Wang D. The Neuroprotective Properties of Hericium erinaceus in Glutamate-Damaged Differentiated PC12 Cells and an Alzheimer's Disease Mouse Model. International journal of molecular sciences. Nov 1 2016;17(11).
Zhang JJ, et al. “Protective Effect of Pyrroloquinoline Quinone against Abeta-Induced Neurotoxicity in Human Neuroblastoma SH-SY5Y Cells.” Neurosci Lett. 464.3 (2009): 165-9.
Zhang S and Yao T. [Estrogen: regulation of amyloid-beta protein metabolism and attenuation of amyloid-beta protein neurotoxicity]. Sheng Li Ke Xue Jin Zhan. 2003 Jul;34(3):197-201.
Zhang XY, Zhang LH, Li CT, Chen WJ, Zhao JB, Wei EQ. [5-lipoxygenase is involved in rotenone-induced injury in PC12 cells]. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences. Mar 2011;40(2):150-155.
Zhao Y, Zhao B. “Natural antioxidants in prevention and management of Alzheimer’s disease.” Front Biosci (Elite Ed). 1.4 (2012): 794-808.
Zhou P, et al. “Acetyl-L-Carnitine Attenuates Homocysteine-Induced Alzheimer-Like Histopathological and Behavioral Abnormalities.” Rejuvenation Res. 14.6 (2011): 669-79.
Zhou X, Zhang F, Hu X, Chen J, Wen X, Sun Y, . . . Song Y. Inhibition of inflammation by astaxanthin alleviates cognition deficits in diabetic mice. Physiology & behavior. Nov 01 2015;151:412-420.
Zhu Y, Prata L, Gerdes EOW, et al. Orally-active, clinically-translatable senolytics restore α-Klotho in mice and humans. EBioMedicine. Mar 2022;77:103912. doi:10.1016/j.ebiom.2022.103912. https://pubmed.ncbi.nlm.nih.gov/35292270/
Zuin M, Cherubini A, Volpato S, Ferrucci L, Zuliani G. Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia. Sci Rep. Jul 16 2022;12(1):12214. doi:10.1038/s41598-022-16476-w. https://pubmed.ncbi.nlm.nih.gov/35842477/